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Vaccination has been one of the most important 
interventions designed to prevent disease to be 
employed on a worldwide basis. Adenoviral vector 
has been extensively studied as a vaccine platform 
because of its ability to induce potent cellular and 
humoral immunity. Consequently, the market 
requirements for adenoviral vectors are increasing, 
creating a need for new methodologies for large-
scale production of concentrated vectors with 
warranted purity and efficacy. This work 
contributes for the improvement of the state of the 
art of adenoviral vectors production process.
Adenovirus as a Biopharmaceutical
Optimisation of vector production
By
Tiago Bruno Pereira Soares Ferreira
Dissertation presented to obtain a Ph.D
degree in Chemical Engineering at the 
Instituto de Tecnologia Química e Biológica,  
Universidade Nova de Lisboa
Oeiras, March  2007
Adenovirus as a Biopharmaceutical
Optimisation of vector production
Tiago Bruno Pereira Soares Ferreira
Dissertation presented to obtain a Ph.D degree in Chemical
Engineering at the Instituto de Tecnologia Química e 
Biológica, Universidade Nova de Lisboa
Supervisors: Paula M. Alves and Manuel J. T. Carrondo
Instituto de Tecnologia Química e Biológica
Universidade Nova de Lisboa
Oeiras, March 2007
ii
Adenovirus as a Biopharmaceutical: Optimisation of vector production
Second edition: May 2007
Copyright number:
Cover images:
Front: Adenovirus particle. Source: image was adapted from the web site 
http://nobelprize.org/nobel_prizes/medicine/laureates/1993/illpres/gene
s-in-pieces.html.
Back: Electron microscope picture of adenovirus particles (up image) and 
microscope picture of 293 cells infected with adenovirus vectors (back 
image).
ITQB/IBET Animal Cell Technology Laboratory
Instituto de Tecnologia Química e Biológica/
Instituto de Biologia Experimental e Tecnológica
Apartado 12, 2781-901 Oeiras, Portugal
Fax: +351 21 442 11 61; Phone: +351 21 446 94 24
http://www.itqb.unl.pt
http//www.ibet.pt
iii
Supervisors:
Dr. Paula Marques Alves, Principal Researcher and Group Leader of the 
Animal Cell Technology Laboratory at ITQB, Oeiras Portugal.
Prof. Dr. Manuel J. T. Carrondo, Professor of Chemical and Biochemical 
Engineering at Universidade Nova de Lisboa, Monte da Caparica, Portugal, 
CEO (Chief Executive Officer) of IBET, Oeiras, Portugal, CSO (Chief 
Scientific Officer) of GenIBET Biopharmaceuticals, Oeiras, Portugal and 
Head of the Animal Cell Technology group at ITQB, Oeiras, Portugal.
Jury:
Dr. John G. Aunins, visiting Professor at ITQB, Oeiras, Portugal and Senior 
Director of Cell Culture Development and Vaccine BioProcess at Merck 
Research Labs., Philadelphia, USA.
Dr. Eric J. Kremer, Group Leader and Director of Research at Institut de 
Génétique Moléculaire de Montpellier CNRS, Montpellier, France.
Dr. Joaquim Sampaio Cabral, Professor at Instituto Superior Técnico, 
Lisboa, Portugal.
Dr. Ana Sofia Coroadinha, Auxiliar Resercher of the associated laboratory 
ITQB/IGC/IBET, Oeiras, Portugal.
iv
Foreword
The present thesis dissertation is the result of four years of research at the 
Laboratory of Animal Cell Technology at ITQB/IBET (Portugal) under Dr. 
Paula M. Alves and Prof. Dr. Manuel J. T. Carrondo Supervision.
This thesis intends to explore the limiting factor on adenovirus vector 
production at high cell densities aiming the understand and improvement 
of the current inefficient process of adenovirus vector production in order 
to respond to the increasing demand of methodologies for the production 
in large scale of concentrated vectors with warranted purity and efficacy.
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Abstract
Adenovirus vectors (AdV) have attracted considerable interest over the 
past decade, with ongoing clinical development programs for applications 
ranging from replacement therapy for protein deficiencies to cancer 
therapeutics to prophylactic vaccines. In fact, in the period 1989-2005,
over 300 clinical trials were conducted using adenoviruses worldwide, 
adenovirus type 5 (Ad5) being the vector of choice. Consequently, 
considerable product process, analytical and formulation development has 
to be carried out in order to respond to the constantly increasing market
requirements for AdV.
One of the major restrictions on AdV production is the so-called “cell 
density effect”, i.e., a drop in cell specific productivity concomitant with 
increased cell concentration at infection (CCI) above 1106 cells/ml. This 
limitation on AdV production has to be fine-tuned in order to obtain higher 
AdV volumetric productivities; this will be the subject of study and 
development in this thesis.
In Chapter I, a state of the art on recent developments and approaches of 
AdV production and purification, including successes and failures in 
veterinary clinical applications to date, is presented.
In Chapter II, the cell density effect is explored. Thus, AdV production at 
cell densities higher than 1×106 cell/ml is evaluated by comparing two
different serum free media (CD 293 medium from Invitrogen and EX-Cell 
medium from JRH). The results show that while EX-Cell medium allows the 
higher maximum cell number (7.5×106 cell/ml), CD 293 is the best option 
for AdV production at high cell densities, allowing infection at CCI of 2×106
cell/ml without significant losses in terms of cell specific productivity. 
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Nevertheless, although CD 293 medium allows cell growth up to 5.5×106
cells/ml, when infection is performed at CCI of 3×106 cell/ml a significant 
drop in cell specific productivity is observed. This phenomenon was 
tentatively attributed to nutrient limitations and/or accumulation of toxic 
byproducts. These byproducts (e.g. lactate) are also associated with an 
increase on osmolality. In addition, the possible need to develop a refeed 
strategy must take into account the consequent increase in osmolality. 
Thus, the effect of osmolality on cell growth and AdV production was also 
evaluated in this Chapter. The capacity of 293 cells to produce AdV showed 
a good tolerance to increases in osmolality.
In chapter III, the limiting factors on AdV production at high cell densities 
are discussed. In Part 1, amino acids, glucose, lactate and ammonia
metabolism are evaluated in non-infected and infected cells at CCI of 1 and 
3106 cells/ml. Threonine, glutamine and glucose were observed to be 
totally consumed on AdV production at CCI of 3106 cells/ml. However, no 
improvements on AdV production were obtained after addition of these 
nutrients at infection time. On the other hand, ammonia was observed to 
be at a toxic concentration for cell growth at the time of infection at this 
CCI. Thus 293 cells were adapted to grow in glutamate supplemented 
medium instead of glutamine, a non-ammoniagenic medium. With this 
strategy a significant decrease on ammonia cell specific production rate 
was obtained with an increase of 1.8 times on the AdV volumetric 
productivity when infection was performed at CCI of 3106 cells/ml. 
Therefore, ammonia is an important factor on AdV production at high cell 
densities. In order to understand the reasons for such inhibition, in Part 2 
ammonia inhibition mechanisms are discussed by comparing both 
ammoniagenic (glutamine supplemented) and non-ammoniagenic media. 
The results show that Intracellular pH (pHi) is severely affected at high 
ammonia concentration, as expected. Besides, these changes on pHi were 
observed to play an important role on cell viability and AdV DNA stability, 
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decreasing the time during which cells are producing AdV and the 
availability of AdV DNA for encapsulation, consequently decreasing the 
amount of bioactive AdV particles produced.
In Chapter III, by adapting the cells to non-ammoniagenic medium, an 1.8 
fold increase on AdV volumetric productivity at CCI 3106 cell/ml was 
obtained, although the “ideal” situation would have been an increase of 3 
times at this CCI; thus, ammonia is an important parameter to be 
considered for infection at high cell densities, but not the only one. Thus,
in Chapter IV, the physiological state of the cells at the time of infection at 
different CCIs is evaluated by following the cell cycle. Therefore, in Part 1,
the evaluation of the cell cycle through the cell culture is shown. At the 
optimal CCI (CCI of 1106 cells/ml) the amount of cells at the S phase of 
the cell cycle was observed to be in its maximal and to decrease with the 
increase on the cell density. In addition, by infecting cells at the same cell 
concentration with different percentages of cells at the S phase of the cell 
cycle an increase on cell specific productivities was observed with the 
increase on the percentage of cells at the S phase of the cell cycle, 
suggesting that the cell specific productivity is cell cycle phase dependent 
at infection time. To clarify this question, in Part 2, 293 cells were 
synchronised at each phase of the cell cycle with chemical compounds and 
infected at the same CCI. The higher cell specific productivity was
obtained when cells were synchronised at the S phase of the cell cycle, 
confirming our previous hypothesis. Thus, since the physiological state of 
the cells is an important parameter to consider at the time of infection on 
AdV production, a strategy avoiding the use of chemical inhibitors was 
developed by using temperature shift. With this strategy a synchronisation
of 57% of the cells at the S phase of the cell cycle by just decreasing the 
temperature to 31ºC during 67h and increasing it again to 37ºC for 72h was 
obtained. By infecting these synchronised cells, an increase of 7.3 times on 
the cell specific productivity was obtained. However, due to losses on cell 
xviability and the higher incubation times necessary to achieve S phase cell 
synchronisation, more studies are still required to fine true the process.
In the Annexes two additional studies are presented. In Annex A, the 
importance of infection kinetics, such as the MOI (Multiplicity Of Infection) 
and HPI (Hours Post Infection) on AdV production process optimisation were 
evaluated. In addition, the use of serum supplemented media were 
compared with a serum free media in terms of cell growth and AdV 
production; in Annex B, the effect of adding vitamins or lipids at the time 
of infection at high cell densities are evaluated, no significant 
improvement on AdV production being obtained.
This thesis presents relevant contributions to the current state of the 
technology of manufacturing AdV. Both medium limitations (either lack of 
nutrients or excessive byproducts production, namely ammonia) and the 
physiological cell state condition at the time of infection were found to be
valuable parameters to be considered for AdV production at high cell 
densities. 
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Sumário
Os vectores adenovirais (AdV) têm atraido bastante interesse durante a 
última decada, com o desenvolvimento de programas de aplicação clinica 
que vão desde a terapia de substituição para défices proteicos a terapias 
contra o cancro e vacinas profiláticas. Na realidade, no periodo 1989-2005,
mais de 300 testes clinicos foram realizados em todo o mundo usando 
adenovirus, maioritariamente adenovirus do tipo 5 (Ad5), sendo um vector 
de excelência. Consequentemente, o desenvolvimento de um processo para 
produção de quantidades consideráveis de producto, analíticos e 
formulações têm que ser realizados de forma a dar resposta ao constante 
aumento dos requerimentos do mercado para os vectores adenovirais. 
Uma das maiores restrições na produção de AdV é o tão chamado “efeito 
da densidade celular”, isto é, uma queda na productividade celular 
específica com o aumento da concentração celular na infecção (CCI) acima 
de 1106 células/ml. Esta limitação na produção de AdV tem que ser 
cuidadosamente analisada de forma a obter elevadas productividades 
volumétricas de AdV; estes vão ser o tema de estudo e desenvolvimento 
nesta tese.
No Capítulo I, é realizado uma revisão do estado de arte sobre os 
desenvolvimentos e estratégias mais recentes para a produção e 
purificação de AdV, incluindo sucessos e insucessos obtidos em aplicações 
clínicas veterinárias.
No Capítulo II o efeito da densidade celular é explorado. Desta forma, a 
produção de AdV a concentrações celulares superiores a 1×106 células/ml é 
avaliada pela comparação de dois meios sem soro diferentes (meio CD 293 
da Invitrogen e o meio EX-Cell da JRH). Os resultados mostram que 
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enquando o meio EX-Cell permite a obtenção do número mais elevado de 
células (7.5×106 células/ml), o meio CD 293 é a melhor opção para a 
produção de AdV a elevadas densidades celulares, permitindo a infecção a 
uma CCI de 2×106 células/ml sem perdas significativas em termos de 
productividade celular específica. De qualquer forma, observou-se que 
apesar do meio CD 293 permitir um crescimento celular até 5.5106
células/ml, a productividade celular específica é dramaticamente afectada 
quando a infecção é realizada à CCI de 3106 células/ml. 
Este fenómeno foi atribuído à limitação de nutrientes e/ou acumulação de 
bioprodutos tóxicos. Estes bioprodutos (ex. Lactato) estão também 
associados a aumentos na osmolalidade. Adicionalmente, a possível 
necessidade de desenvolver um estratégia de “refeed” deve ter em 
consideração o consequente aumento na osmolalidade. Assim, o efeito da 
osmolalidade foi também avaliado neste capítulo em termos de 
crescimento celular e produção de AdV. As células 293 mostraram grande 
tolerância aos aumentos na osmolaridade na produção de AdV.
No Capítulo III, são discutidos os factores limitantes na produção de AdV a 
elevadas densidades celulares. Na parte 1, o metabolismo de aminoácidos, 
glucose, lactato e amónia é estudado em células não infectadas e
infectadas à CCI de 1 e 3106 células/ml. Observou-se que a treonina, 
glutamina e glucose foram totalmente consumidos na producção de AdV à
CCI de 3106 células/ml. Mas não foi obtida qualquer melhoria na produção 
de AdV depois da adição destes nutrientes na altura da infecção. Por outro 
lado, foi observada uma elevada concentração de amónia na altura da 
infecção a esta CCI, considerada tóxica para o crescimento celular. Assim 
sendo, as células 293 foram adaptadas a crescer em meio suplementado 
com glutamato em vez de glutamina, num meio não-amóniagênico. Com 
esta estratégia obteve-se uma diminuição significativa na taxa específica 
de produção de amónia com um aumento de 1.8 vezes na productividade 
volumétrica de AdV quando a infecção é realizada à CCI de CCI 3106
xiii
células/ml.
Desta forma, demonstrou-se que a amónia é um factor importante para a 
produção de AdV a elevadas densidades celulares. Por forma a comprender 
os motivos para esta inibição, na Parte 2, os mecanismos de inibição pela 
amónia são discutidos pela comparação de ambos os meios amóniagênico 
(meio suplementado com glutamina) e não-amóniagênico. Os resultados 
mostram que, como esperado, o pH intracelular (pHi) é fortemente
afectado a elevadas concentrações de amónia. Por outro lado, observou-se 
que estas alterações no pHi têm um importante impacto na viabilidade 
celular e na estabilidade do DNA dos AdV, diminuindo o tempo durante o 
qual as células produzem AdV e a quantidade de DNA de AdV disponível 
para encapsulação, diminuindo consequentemente a quantidade de
particulas bioactivas de AdV produzidas.
No Capítulo III, ao adaptar as células ao meio não-amóniagênico, foi obtido 
um aumento de 1.8 vezes na productividade volumétrica de AdV à CCI de 
3×106 células/ml. No entanto a situação “ideal” seria um aumento de 3 
vezes a esta CCI; deste modo mostrou-se que apesar da amónia ser um 
factor importante a ser considerado para a infecção a elevadas densidades 
celulares não é o único a ter em consideração. Assim, no Capítulo IV, o 
estado fisiológico das células na altura da infecção a diferentes CCIs é
estudado seguindo o ciclo celular: Na Parte 1, é feito o estudo do ciclo 
celular durante o crescimento celular. Observou-se, à CCI óptima (CCI de 
1×106 células/ml), que a quantidade de células na fase S do ciclo celular é
máxima e diminui com o aumento da densidade celular. Além disto, ao 
infectar células à mesma concentração com diferentes percentagens na 
fase S do ciclo cellular, registou-se um aumento na productivade celular 
específica com o aumento da percentagem de células na mesma fase, 
sugerindo que a productividade celular específica é dependente do ciclo 
celular na altura da infecção. Para clarificar esta questão, na Parte 2, as 
células 293 foram sincronizadas em cada uma das fases do ciclo celular 
xiv
com compostos químicos e infectadas à mesma CCI. A maior 
productividade celular específica foi obtida quando as células foram 
sincronizadas na fase S do ciclo celular, o que confirma a nossa hipótese 
anterior. Assim, uma vez que o estado fisiológico das células é um 
parâmetro importante a considerar na altura da infecção na produção de 
AdV, foi desenvolvida uma estratégia para sincronizar células, sem recorrer 
ao uso de inibidores químicos, usando alterações da temperatura. Com esta 
estratégia foi possível obter uma sincronização de 57% das células na fase S 
do ciclo celular apenas descendo a temperatura para 31ºC durante 67h e 
aumentando-a novamente para 37ºC durante 72h. Ao infectar estas células 
sincronizadas obteve-se um aumento de 7.3 vezes na productividade 
celular específica. Mas, devido a perdas na viabilidade celular e aos 
elevados tempos de incubação necessários para obter sincronização na fase 
S, são necessários mais estudos para “afinar” o processo.
Em anexo são mostrados dois estudos adicionais. No Anexo A, é avaliada a 
importância de cinéticas de infecção na optimisação do processo de 
produção de AdV, tais como a MOI (Multiplicidade de Infecção) e HPI (Horas 
Pós Infecção). Em adição, o uso de meios suplementados com soro foi
comparado com um meio livre de soro em termos de crescimento celular e 
produção de AdV; no Anexo B, é avaliado o efeito da adição de vitaminas 
ou lipidos na altura da infecção a elevadas densidades celulares, sem se ter 
verificado um aumento relevante em termos de produção de AdV.    
Esta tese apresenta contribuições relevantes para a actual tecnologia de 
produção de AdV. Tanto a limitação do meio (quer por falta de nutrientes 
quer por produção excessiva de bioproductos, nomeadamente a amónia) e 
o estado fisiologico das células no momento da infecção foram 
identificados como parâmetros valiosos a ser considerados na produção de 
AdV a elevadas densidades celulares.
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Abstract
Vaccines are the most effective and inexpensive prophylactic tool in human 
and veterinary medicine. Ideally, vaccines should induce a lifelong 
protective immunity against the target pathogen while not causing clinical 
or pathological signs of diseases in vaccinated people or animals. However 
such ideal vaccines are rare in the veterinary field. Many vaccines are 
either of limited effectiveness or have harmful side effects. In addition, 
there are still severe diseases with no effective vaccines. A very important 
criterion for an ideal vaccine in veterinary medicine is low cost; this is 
especially important in developing countries and even more so for poultry 
vaccination, where vaccines must sell for a few cents a dose. 
Traditional approaches include inactivated vaccines, attenuated live 
vaccines and subunit vaccines. Recently, genetic engineering has been 
applied to design new, improved vaccines. Adenovirus vectors are highly 
efficient for gene transfer in a broad spectrum of cell types and species. 
Moreover, adenoviruses often induce humoral, mucosal and cellular 
immune responses to antigens encoded by the inserted foreign genes. 
Thus, adenoviruses have become singular vectors of choice for delivery 
and expression of foreign proteins for vaccination. Consequently, the
market requirements for adenovirus vaccines are increasing, creating a 
need for production methodologies of concentrated vectors with 
warranted purity and efficacy. This chapter summarizes recent 
developments and approaches of adenovirus production and purification, 
including successes and failures in veterinary clinical applications to date.
At the end of the chapter, a brief outline of the scope intended for this 
thesis is presented.
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1. ADENOVIRUS VACCINATION HISTORY 
The history of veterinary vaccine development starts with the well-known 
story of Louis Pasteur and his rabbit spinal cord vaccine and continues to 
this day with the demonstration of protection in animals by rabies virus 
reverse transcriptase DNA plasmid vaccination (Plotkin 2000). In between, 
in 1947, Frenkel used suspensions of the epithelium obtained from the 
tongues of recently slaughtered healthy cattle that were maintained in 
vitro and subsequently infected in a manner similar to that used today with 
Baby Hamster Kidney (BHK) cells to produce Foot and Mouth Disease Virus 
(FMDV). The Frenkel procedure became the corner stone of vaccine 
production for many years and paved the way for modern biotechnology as 
we know it (Doel 2003). More recently, recombinant pox viruses have been 
generated for vaccination against heterologous pathogens, using vaccinia-
vectors, expressing the rabies virus glycoprotein and Newcastle disease 
virus fusion and hemagglutinin glycoproteins, the first applications of 
genetically engineered vaccines (Paoletti 1996).
Traditional vaccination involves the use of inactivated, live-attenuated or 
subunit vaccines. Inactivated, or “killed” vaccines, consist of treated 
microorganisms that are unable to replicate; however they do not elicit 
protein production in the cytosol and hence viral antigens cannot be 
presented by MHC class I molecules, thus cytotoxic CD8 T cells are not 
generated. Live-attenuated vaccines are generally far more potent educing 
a greater number of relevant effector mechanisms, including cytotoxic CD8 
T cells. Nevertheless, these vaccines sometimes have residual 
pathogenicity (Miller et al., 1993), or a pathogenic virus strain may re-
emerge by a further series of mutations (Wood and Macadam 1997). 
Subunit vaccines would be as effective as live whole organisms, inherently 
safer than vaccines based on whole organisms, but they are not strongly 
immunogenic, being particularly difficult to obtain MHC class I specific 
responses (Yokoyama et al., 1997; Giese 1998; Dunham 2002). The 
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development of vaccines therefore remains an important goal of 
immunology. Moreover, there remains a need for further vaccines that can 
reduce the economic impact of disease in production animals.
The ideal vaccine should be 100% efficacious in preventing infection, 
although this is totally unrealistic. Therefore, the “realistic” vaccine 
should provide greater than 90% efficacy in disease prevention within a few 
days up to a couple of weeks of a single administration. Furthermore, in 
order to reduce the cost of regular reimmunizations and ensure receipt of a 
complete vaccination schedule, this protection should be of long duration, 
and should use a minimal number of doses. Additionally, an “ideal” vaccine 
would also stimulate mucosal immunity, since the majority of viruses enter 
via mucosal surfaces; thus, the “perfect” vaccine should be designed to be 
delivered by mucosal routes, i.e., intranasal or oral delivery is preferable. 
Vaccines also need to be safe and not cause any adverse side reaction, 
such as immunosuppression or interference with immunity to other 
vaccines given simultaneously. Finally, the vaccines need to be both 
genetically and thermally stable. Genetic stability must be present to 
ensure the absence of reversion of the live vaccine to the virulent organism 
which might cause disease; and thermal stability is critical since the 
maintenance of the cold chain is not always guaranteed from 
manufacturing to delivery. A very important desired characteristic is to 
have vaccines which can be delivered to animals at a very young age and 
stimulate immunity in the presence of innate, passive immunity (Babiuk et 
al., 1996; Jalava et al., 2002). Another very important criterion for an 
ideal vaccine in veterinary medicine is low cost; this is especially important 
in developing countries and for poultry vaccines, in which the vaccines 
must sell for a few cents a dose. Unfortunately, such ideal vaccines are 
rare in the veterinary field; additionally, there are still severe diseases 
with no effective vaccines. 
The history of heterologous gene expression in adenovirus (Ad) goes back to 
the discovery of simian virus 40 (SV40) contamination in the 1950s of 
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inactivated Ad strains 1-5 and 7 vaccines during adaptation to growth in 
rhesus monkey kidney cells; it was observed that the SV40 T-antigen 
occasionally incorporated into the Ad genome which led to the realization 
that Ad could be used to express heterologous genes (Lewis 1998). Then 
recognition that purified replication-defective Ads could be propagated on 
293 cells without helper viruses paved the way toward intentional 
production of genetically modified Ads (Graham et al., 1977). The 
popularity of Ad as a recombinant viral vector is largely due to the 
successful and safe immunization of millions of US military recruits in 1971 
with enterically coated Ad4 and Ad7 as a prevention against acute 
respiratory disease (ARD) outbreaks (Bloom and Lambert 2003). Following 
these first trials, a number of recombinant Ad (rAd) have recently been 
constructed and tested not only for humans but also for veterinary 
vaccination (Randrianarison-Jewtoukoff and Perricaudet 1995; Yokoyama 
et al., 1997).
Ads are highly efficacious vaccine carriers with strong immunogenicity. 
Although the ability of Ad vectors (AdV) to elicit antigen-specific CD8 and 
CD4 T cells is well described, little is known about the kinetics or nature of 
the immune response following Ad immunization (Yang et al., 1996; Jooss 
et al., 1998). However, Yang et al. (2003) observed that AdV have i) the 
ability to deliver large amounts of antigen into the lymphoid tissues, ii) the 
ability to induce rapid expansion and migration of CD8 T cells throughout 
the lymphatic system, and iii) the ability to produce a sustained, high-level 
CD8 T cell response, that may explain the strong immunogenicity of these 
vectors.
The use of rAd as a veterinary vaccine has many advantages: i) they can 
infect a wide variety of dividing or non dividing cells; ii) Ad infections are 
ubiquitous and are normally without significant or severe clinical symptoms
(Russell 2000); iii) they can be administered orally (Babiuk and Tikoo 2000); 
iv) Ads have their genome well characterised (Imler 1995; Randrianarison-
Jewtoukoff and Perricaudet 1995); v) they can accommodate up to 8 kb of 
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foreign genetic material (Bett et al., 1993); vi) their genome rarely 
integrates into the host chromosome (Harui et al., 1999); vii) techniques 
are well established for the construction of AdV (Danthinne and Imperiale 
2000); and viii) they have the ability to replicate at high titers in 
complementing cell lines (Kamen and Henry 2004). 
2. ADENOVIRUS BIOLOGY
Ad is a non-enveloped, icosahedral virus of 60 to 90 nm with a linear 
duplex DNA genome of about 36 kb. The genome is divided into early (E) 
and late (L) genes, expressed, respectively, before and after replication of 
the viral chromosome (Figure 1.1). E1 gene products are involved in the 
control of viral gene transcription, shut-off of cellular proteins and cellular 
transformation. The E2 gene codes for proteins involved in viral 
replication, including a DNA binding protein involved in DNA elongation 
(E2A) and a DNA polymerase (E2B); E3 gene, dispensable for Ad replication, 
codes for proteins that interfere with the host immune response against 
virus infection; finally, the E4 genes are involved in the transition from 
early to late gene expression, the shut-off of host-cell gene expression, the 
viral replication and the assembly of the virion, (see Russell (2000) and 
Imler (1995) for reviews). First-generation vectors are usually deleted in 
their E1 and E3 regions; however, when production is performed on 293 
cells, recombination between the left terminus of first-generation AdV and 
partially overlapping E1 sequences in the cellular genome may result in the 
generation of E1-positive, replication-competent Ad (RCA) (Murakami et 
al., 2002), a serious safety concern if non-replicating vectors are desired. 
Second-generation vectors are replicative-defective AdV, which are further 
deleted in E2A, E2B or E4, showing reduced immunogenicity and RCA 
generation, but engineering of stable cell lines that complement these 
vectors can be cumbersome and lead to poor cell growth and viral titers
(Volpers and Kochanek 2004). 
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Figure 1.1. Schematic representation of the adenoviral genome organization
AdV have been developed either as replication-competent, with the 
expression cassette for the foreign antigen in place of the E3 genes, or as 
replication-defective viruses, when the antigen expression cassette 
replaces the E1 genes (Imler 1995). Despite the fact that it would be 
preferable to work with replication-defective virus, different studies have 
supported the use of replication-competent AdV in veterinary vaccination, 
since the ability of the replication-defective form to induce mucosal 
immunity and to protect against a respiratory challenge, following 
immunization, was reported to be limited (Papp et al., 1997; Fischer et al., 
2002). Moreover, replication-competent AdV based vaccines were known to 
have the potentiality to over-ride maternal derived immunity (Papp et al., 
1999; Fischer et al., 2002). Additionally, cattle vaccination with both AdVs 
against herpesvirus-1 showed that the use of the replication-defective form 
induced lower titers of antibody than the replication-competent form in 
intratracheal/subcutaneous immunization (Reddy et al., 2000). 
3. SPECIES-SPECIFIC PLATFORMS
Currently, human AdV represents one of the most efficient vector systems 
for delivery of vaccine antigens. However, the use of human Ad (HAd) as a 
vaccine delivery system in non-human animals is still limited. Since non-
HAds are species specific, the development of animal specific Ad as a 
                                                                     Introduction
11
vaccine delivery system would be a logical choice. Thus, Ads isolated from 
species other than man have generated increasing interest, in particularly: 
i) canine Ad (CAd), that has the ability to replicate and persist locally in 
the upper respiratory tract of puppies in the face of maternal derived 
antibodies when administered via the intranasal route and use both 
depedent and independent coxsackievirus group B and Ad receptor (CAR) 
pathays to enter the cells (Soudais et al., 2000; Fischer et al., 2002); 
ii) avian Ad, the subject of numerous investigations, has a number of 
features that make them attractive to the poultry industry: ease of 
propagation, ease of administration (water, aerosol or injection) and a 
large range of serotypes that vary in virulence. Chicken embryo lethal 
orphan (CELO), classified as the type 1 fowl Ad (FAd), is the most studied 
vector. This virus, like other typical avian Ad, has a much larger genome 
than mammalian Ad. Despite its large scatter, it has never been associated 
with serious disease or economical losses in the poultry industry. It can be 
isolated from healthy chickens and does not induce clinical signs when 
experimentally inoculated in chickens. Also this virus use both dependent 
and independent CAR pathways to enter the cells (Sheppard et al., 1998; 
Soudais et al., 2000); 
iii) porcine Ad (PAd), that, depending upon serotype, can be grown in pig 
kidney, testis, retina, thyroid cells, human kidney, canine melanoma and 
calf kidney cells, do not require adjuvants for the induction of proper 
immune responses. Infection is generally sub-clinical causing no adverse 
effects in producing pigs, with PAd also isolated from apparently healthy 
pigs. PAd is species specific having only been isolated from swine, reducing 
the possibility of its spread to other animal or man following 
administration. PAd could induce both systemic and mucosal antibody 
responses (Hammond et al., 2001a; Zakhartchouk et al., 2003); 
iv) and bovine Ad serotype 3 (BAd3), that, like PAd, do not require 
adjuvants for the induction of proper immune response, and has been used 
due to its lack of virulence. Moreover, experimental infections of calves 
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with BAd3 failed to produce either clinical signs or gross lesions, but all 
animals seroconverted. The cell entry pathway of BAd3 is not well 
understood (Benko and Harrach 1998; Reddy et al., 2000).
4. APPLICATIONS
4.1. Adenovirus Vaccination in companion animals
4.1.1. Feline Immunodeficiency Virus (FIV) 
The infection of cats with FIV results in an immunosuppressive disease that 
is transmitted by blood and saliva. FIV invades and destroys the 
monocyte/macrophage system and infects B-cells (Uhl et al., 2002). 
Different approaches have been made trying to immunize cats against FIV; 
so far, no effective vaccine has been made. Gonin et al., (1995), 10 years 
ago, constructed a replication-defective HAd5, containing the envelope 
protein ENV gene of FIV; however, despite the fact that an antibody 
response to pseudorabies virus in cats showed the potential of rHAd5 
vectors to be used in this species, cats injected with 1010.8-1011.8 of 50 
percent tissue culture infectious dose (TCID50) adjuvanted with montanide 
ISA 708 (water in non mineral oil) or with montanide ISA 206 (double 
water/mineral oil/water) of this AdV did not develop detectable antibody 
response against ENV. Moreover, it was observed that even if high titers of 
antibodies against ENV products are induced, they could still be insufficient 
for protection (Gonin et al., 1995). Since then, no further work has 
apparently been performed concerning the use of AdV as a potential 
vaccine against FIV.
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4.1.2. Canine Distemper Virus (CDV) 
CDV induces fatal diseases including encephalitis with demyelination, 
diarrhea and respiratory disorders in dogs. Although conventional live 
modified vaccines are commercially available and widely used in the field, 
their efficacy is limited in the presence of maternally-derived antibodies
(Barrett 1999). Thus, a new and improved CDV vaccine which could 
overcome this limitation would constitute a significant improvement. The 
construction and characterization of the first replication-competent rCAd2 
started recently. The genes that code for CDV hemagglutinin (HA) (Fischer 
et al., 2002; Hirama et al., 2003) or fusion (F) (Fischer et al., 2002)
proteins were inserted in two CAd2s and used as a candidate vaccine in 
puppies. It was reported that intranasal vaccination with a mixture 
containing 105.8 TCID50 of which rCAd2 provided an excellent level of 
protection in seronegative puppies, inducing almost complete protection. 
In contrast, intranasal immunization of puppies born to CDV and CAd2 
immune dams failed to activate specific and protective immune responses. 
However, when the same puppies were vaccinated subcutaneously, 
significant seroconversion and solid protective immunity were triggered. 
Furthermore, a significant priming of memory responses was evidenced 
immediately after challenge, this constituting an efficient strategy to 
overcome both passive and active Ad specific immunity in the dog.  
4.1.3. Rabies Virus (RV)
Rabies still presents a health threat not only to humans but also to dogs 
and cats, being the dog the only important vector for humans, especially in 
less developed nations where uncontrolled canine rabies often is endemic. 
A replication-competent and -defective HAd5 expressing a rabies 
glycoprotein (RG) has been developed, inducing immunity to rabies in 
rodent, canine, foxes and skunk when given by intramuscular, 
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subcutaneous or intranasal routes with a dose of 108 TCID50/animal. 
However, oral immunization failed to induce a measurable antibody 
response to RV using the same dose (Xiang et al., 1996; Vos et al., 2001). 
Dogs previously vaccinated with commercially available vaccines, 
immunized with 107 plaque forming unit (pfu)/animal of a replication-
defective HAd5 expressing the RG, have developed higher titers of viral 
neutralizing antibodies against RV 10 days after vaccination when 
compared with conventional vaccines under similar conditions. Moreover, 
the immunization of dogs with the commercial non Ad vaccines is required 
yearly or, at best, every 3 years, depending on the type of vaccine. On the 
other hand, the higher antibody titers obtained with Ad vaccines against RV 
would reduce the frequency of dog immunization, reducing the costs for 
pet owners (Tims et al., 2000). One important advantage of this 
recombinant vaccine is the fact that the immune response to the RG was 
shown not to be impaired by maternal immunity; thus, this Ad vaccine is 
highly suitable for neonatal immunization (Wang et al., 1997).
4.2. Adenovirus Vaccination in Poultry
4.2.1. Avian Infectious Bronchitis Virus (IBV) 
IBV is a highly contagious pathogen of poultry causing significant morbidity 
and mortality. Depending on the strain, IBV can target the respiratory 
tract, kidney and oviducts and result in nephritis and reduced egg 
production. In addition, more than 20 IBV serotypes have been identified 
worldwide and new serotypic variants have been identified as a result of 
the widespread use of live attenuated vaccines. Different approaches have 
been developed in order to generate a more efficacious vaccine against 
IBV. The expression of S1, a glycoprotein involved in the attachment of 
cellular receptors, by a vaccinia virus was able to induce virus-neutralizing 
antibodies to IBV when delivered to mice; however, multiple injections are 
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required to achieve a reasonable degree of protection. Recently, a FAd 
expressing the S1 of IBV has been developed (Johnson et al., 2003). A 
single dose of 106 TCID50/animal was shown to be sufficient to obtain 
complete protection of chickens at the trachea, the primary site of 
infection by IBV. Moreover, even in the face of FAV maternal antibodies, a 
high level of protection was achieved (Johnson et al., 2003).    
4.2.2. Infectious Bursal Disease Virus (IBDV) 
IBDV induces an immunosuppressive disease of chickens by destruction of 
the B-lymphocytes. Current vaccination alternatives consist of either live 
virus or inactivated oil-emulsion vaccines, which induce serum antibody 
production in breeding hens after natural exposure; they are transferred to 
the progeny chicks via the yolk sac providing protection for the first critical 
weeks after hatching (Muller et al., 2003). The construction of a rFAd10 
containing the VP2 gene from IBDV has been described (Sheppard et al., 
1998). This recombinant vaccine was shown to induce an immune response 
in chickens to VP2 after vaccination with 107 pfu/animal. Moreover, after 
challenge with IBDV, intravenously, intraperitoneally, subcutaneously or 
intramuscularly vaccinated chickens were protected, although no 
protection was observed in conjunctival sac vaccinated chickens (Sheppard 
et al., 1998).
4.3. Adenovirus Vaccination in Swine
4.3.1. Classical Swine Fever Virus (CSFV) 
Classical swine fever (CSF), also known as hog cholera, is a serious and 
contagious viral disease of pigs with a high mortality rate, difficult to 
control in areas of high pig or wild boar densities, being the most 
economically important disease of swine in areas of intensive pig farming. 
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For this reason, CSF is included in the A list of infectious diseases of the 
highest importance for international trade. Thus, it is highly relevant to 
develop efficacious vaccines for the control of CSFV in domestic pigs and in 
wild boar. Prophylactic vaccination is still carried out in many parts of the 
world (Paton and Greiser-Wilke 2003). New vaccine developments have 
included a number of different strategies for delivering the major envelope 
glycoprotein, E2, against which most neutralizing antibodies are directed
(van Oirschot 2003). Hammond et al. (2000), constructed the first rPAd 
expressing the E2 protein and showed that a single dose of 107
TCID50/animal in tissue culture supernatant, when administered 
subcutaneously, is sufficient to completely protect pigs against 
subcutaneously challenge. Later, the same authors showed that when the 
challenge is administered orally, only 60% of the animals were protected
(Hammond et al., 2001b); more, recently, it was shown that pigs given two 
oral doses of 106 TCID50/animal of rPAd were completely protected from 
the disease (Hammond et al., 2003).
4.3.2. Pseudorabies Virus (PrV) 
PrV is an alpha herpesvirus which causes the economically important and 
widespread Aujeszky’s disease (AJD) in pigs. PrV is a highly neurotropic 
virus causing nervous and respiratory complications in pigs, the natural 
host, and in a variety of other animal species. Vaccination against AJD is 
widely practised with live attenuated or killed whole virus vaccines. 
However, neonatal immunization is often limited in the presence of 
maternally-derived antibody, which inhibits the immune response against 
both vaccines (Roth 1999). Recently, the use of rAd vaccines carrying 
individual PrV genes were constructed as a safe alternative. Glycoproteins 
gD, gB and gC of PrV were chosen on the basis of their role in eliciting a 
protective immune response against virus infection.  It was shown that 
piglets vaccinated  intramuscularly with 108.6-109.6 TCID50/animal one day 
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after birth, with replication-competent HAd5 harbouring these three genes, 
developed similar neutralizing antibody responses independently of the 
presence or absence of maternal antibodies and were partially protected 
against challenge 16 weeks later (Monteil et al., 2000). For pigs that are 
slaughtered a few months after birth, one-shot vaccination at birth could 
provide protection of sufficient duration. Finally, two doses of 2 ml of 
clarified tissue culture supernatant containing 105.4 TCID50 of rPAd 
expressing the PrV gD gene were administered subcutaneously and showed
to protect pigs after challenge. Post-morten, gross lesions of pneumonia 
were found in the lungs of pigs given a single dose of vaccine; the lungs of 
pigs given two doses were free from disease (Hammond et al., 2001a).
4.3.3. Foot and Mouth Disease Virus (FMDV)
Foot and mouth disease (FMD) is a severe, clinically acute, vesicular 
disease of cloven-hoofed animals including domesticated ruminants, pigs 
and more than 70 wildlife species. Pigs are recognized as a significant 
factor in the spread of the disease since a single pig releases as much 
aerosol virus as 3000 cattle in a short period of time (Alexandersen et al., 
2003; Thomson et al., 2003). The economic and social impact of FMD can 
be catastrophic when an outbreak occurs in FMD-free countries populated 
with immunologically naive animals. The current vaccine is a chemically 
inactivated preparation of concentrated infected cell culture supernatant. 
However, FMD-free countries generally prohibit its use because of the lack 
of an approved diagnostic test that can reliably distinguish vaccinated from 
infected animals. Moreover, current vaccines can induce a protective 
response only after approximately 7 days post vaccination; this is a critical 
issue in disease-free countries, where, in the case of FMD outbreaks, a 
rapid control in preventing the spread of the disease is crucial (see Doel 
(2003) for a review). Thus, there is a need to develop disease control 
strategies relying on more rapidly induced protection. Mayr et al. (1999)
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developed a replication-defective HAd5 vector containing the capsid 
polypeptide P1 and the viral 3C protease coding regions, necessary for 
processing P1 to the capsid proteins VP0, VP3 and VP1, from the FMDV 
strain A12. They observed that vaccinated swine with 1×108 pfu/animal in 
PBS developed antibodies against FMDV structural proteins and an FMDV-
specific neutralizing antibody response which seems to increase slightly by 
boosting the swine with a second inoculation of 5×108 pfu/animal in PBS at 
4 weeks post-initial vaccination (Mayr et al., 2001). This vaccination 
protocol was shown to offer a significant degree of protection to the pigs, 
as five of six pigs were completely protected, while the remaining animal 
had significantly reduced signs of disease. Later, Moraes et al. (2002)
showed that a single dose of 5×109 pfu/animal in PBS of a replication-
defective HAd5 expressing the P1 coding region of FMDV strain A24 
completely protected pigs against homologous challenge 7, 14 or 42 days 
after vaccination. Since efficacious vaccination is strain dependent and the 
infection with one serotype does not confer protection against another, 
HAd5 bicistronic vector vaccines have been developed (Wu et al., 2003), 
decreasing the cost for multivalent adenoviral FMD vaccines. For the 
construction of these vectors, the P1 capsid coding region for both A24 and 
O1 strains and the 3C protease coding region of A12 strain were used. 
However, the neutralizing antibody response after vaccination with 2.5×109
pfu/animal in PBS of the bicistronic vector was considerably lower than 
that induced by a commercial FMD vaccine or the monovalent Ad-A24 
vaccine (Moraes et al., 2002). Recently, a new strategy based on the fact 
that FMDV is highly sensitive to alpha/beta interferon (IFN-/) have been 
developed using a replication-defective HAd5 (Chinsangaram et al., 2003; 
Moraes et al., 2003). This strategy has been shown to completely protect 
pigs after vaccination with 109 pfu/animal when challenged 24 h later with 
virulent FMDV.  
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4.3.4. Porcine Respiratory and Reproductive Syndrome Virus 
(PRRSV) 
PRRSV is the causative agent of an economically important pig disease, 
with a worldwide distribution, characterized by reproductive failure in 
sows and respiratory problems in unweaned and growing pigs. Swine 
macrophage is the only cell type known to support PRRSV replication, 
making commercial production impossible. Direct contact between 
infected and naive pigs is the predominant route of PRRSV transmission. 
Moreover, pneumonia caused by PRRSV infection is more severe in young 
pigs compared to adults and may be complicated by concurrent bacterial 
infection (Rossow 1998). Gonin et al. (1999) observed that PRRSV infected 
pigs present circulating antibodies responsible for viral neutralization 
mainly directed against GP5, an envelope protein. Gagnon et al. (2003)
constructed a replication-defective HAd5 expressing the GP5 protein and 
used this recombinant virus to immunize pigs using two intradermal 
injections with 5×108-1×109pfu/animal in a mixture containing 100 L of 
PBS and 100 L of poloxamer SP1017 at 0.02%. It was observed that 
following challenge given intranasally 14 days after the booster, pigs 
produced high antibody titers to GP5 protein. Moreover, vaccinated pigs 
presented specific immune memory which, following a subsequent PRRSV 
infection, resulted in a rapid clonal expansion of memory cells to the 
neutralizing epitopes of the authentic viral GP5 protein.     
4.3.5. Transmissible Gastroenteritis (Corona) Virus (TGEV) 
TGEV infects the enteric and respiratory tissues of newborn piglets 
resulting in mortalities approaching 100%. The virus infects epithelial cells 
and, in some cases, lung macrophages (Garwes 1988). There are several 
commercially available TGEV vaccines, both inactivated and attenuated; 
these do not fully protect piglets. Several attempts have been made to 
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develop efficacious recombinant TGEV vaccines (Tuboly and Nagy 2001). 
The spike protein (S) was identified as the major inducer of TGEV-
neutralizing antibodies and it mediates binding of TGEV to its cellular 
receptor (Jimenez et al., 1986). Thus, HAd5 expressing the S protein was 
constructed and used to study the induction of antibodies providing 
protection in swine (Torres et al., 1995). It was observed that porcine 
serum, elicited by 109 pfu/animal in PBS of this recombinant, when mixed 
with a lethal dose of virus prior to administration to susceptible pigs, 
prevented the replication of virulent TGEV administered orally as virus-
antibody mixtures and fully protected swine from clinical signs and death. 
Moreover, the used dose did not produce any clinical symptoms in any of 
the more than 50 animals inoculated up to 10 weeks after inoculation
(Torres et al., 1996), suggesting that this vector can be used as a live 
vaccine in swine without secondary complications associated with the 
vector. However, a PAd vector could be more effective than HAd. Thus, 
Tuboly and Nagy (2001) constructed a rPAd5 expressing the TGEV protein. 
It was observed that a single oral dose of 5×106 pfu/animal of the 
recombinant virus was sufficient to induce both a systemic and a local 
humoral immune response (Tuboly and Nagy 2001). Unfortunately challenge 
experiments were not carried out. 
4.3.6. Swine Influenza Virus (SIV) 
SIV is a widespread and important pathogen in species as diverse as 
poultry, swine, marine mammals and humans. In pigs, influenza can occur 
either as an enzootic problem in a herd or, more commonly, as explosive 
outbreaks of acute respiratory disease. Although rarely fatal, swine 
influenza can be of substantial economic impact (van Reeth and Nauwynck 
2000). In addition, there is growing concern for the potential for synergistic 
infections with influenza and PRRSV. Beyond the impact of influenza for 
the swine industry, pigs are also very important in the global ecology of 
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influenza A viruses in humans (Zhou et al., 1999). SIV vaccines that are 
commercially-available are inactivated, whole-virus or subunit vaccines. 
While these vaccines may decrease the incidence and severity of clinical 
disease, they do not consistently provide complete protection from virus 
infection. Two replication-defective HAd5 were developed as potential 
vaccines against SIV: rHAd5 expressing the influenza virus H3 
haemagglutinin (HA) (Tang et al., 2002; Wesley et al., 2004) inducing 
predominately a subtype-specific humural immune response (Macklin et al., 
1998); and rHAd5 expressing the nucleoprotein (NP) (Wesley et al., 2004), a 
group-specific stimulating cytotoxic T lymphocytes for cross-reactive 
immunity to all influenza A subtypes (Ulmer et al., 1998). It was observed 
that the immunization of mice with 5×108 TCID50/animal and pigs with 
2×1010 TCID50/animal in PBS with the first recombinant, described above, 
developed high levels of virus-specific hemagglutination-inhibition antibody 
to SIV by 4 weeks post vaccination and the animals were partially 
protected. On the other hand, pigs vaccinated with 2×1010 TCID50/ml in PBS 
of both recombinant viruses in a mixture were completely protected.
4.4. Adenovirus Vaccination in Cattle
4.4.1. Bovine Viral Diarrhea Virus (BVDV) 
BVDV is responsible for reduced milk production, reduced reproductive 
performance and growth retardation. In addition, acute infection in adult 
cattle, congenital defects and increased neonatal mortality are also clinical 
manifestations of BVDV infection (Goens 2002). Finally, it was reported 
that BVDV may play an indirect role in immunosuppression (Wellenberg et 
al., 2002). Currently, inactivated and modified-live vaccines are used; 
however, both types of vaccines have significant shortcomings. A rHAd5 
expressing the nucleocapsid C protein (p14), that is highly conserved
among many different pestiviruses, to which BVDV belongs, was 
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constructed and shown to induced both humoral and cellular immune 
responses after vaccination with 109 pfu/animal, in a mouse model (Elahi 
et al., 1999a). The E2 protein of BVDV, which is a major viral glycoprotein, 
was also used for mice immunization using the same vector and dose (Elahi 
et al., 1999b). A strong humoral immune response was detected as the 
presence of a strong memory response to the E2 protein. Both strategies 
used an inducer/promoter allowing the generation of rAd in which the 
production of the transgene may be toxic and permitting the control of the 
transgene expression in vitro and in vivo. Finally, a rBAd3 expressing BVDV 
E2 protein was constructed and shown to induce BVDV E2-specific mucosal 
and systemic immune responses after intranasal immunization with 107
pfu/animal of cotton rats (Baxi et al., 2000). Despite the fact that mice 
immunized with recombinant fowl pox virus or with a DNA vaccine 
expressing E2 glycoprotein induced E2-specific immune responses, it was 
also observed that the neutralization titers were low (Baxi et al., 2000).
4.4.2. Bovine Parainfluenza Virus Type 3 (bPIV3) 
bPIV3 has been isolated from normal cattle, cattle showing signs of 
respiratory disease and aborted fetuses. An intramammary inoculation of 
bPIV3 resulted in respiratory signs, fever and malaise. Moreover, the milk 
showed a color change, an increased pH and increased numbers of 
glandular epithelial cells, neutrophils, lymphocytes and monocytes
(Wellenberg et al., 2002). Currently, multivalent vaccines containing killed 
bPIV3 are used. Breker-Klassen et al. (1995) constructed two rHAd5 
encoding either the F or the HN protein of bPIV3. It was shown that 
intranasal vaccination with 5×107 pfu/animal in PBS of cotton rats 
produced a strong serological response within 21 days which increased with 
the second vaccination. Moreover, F and HN proteins produced by rHAd5 
either alone or in combination were sufficient to induce a protective 
immune response (Breker-Klassen et al., 1995).
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4.4.3. Bovine Herpes Virus 1 (BHV-1)
BHV-1 causes a variety of diseases in cattle including infectious bovine 
rhinotrachitis, infectious pustular vulvo-vaginitis, conjunctivitis and 
occasionally meningo-encephalitis. Live attenuated and killed vaccines are 
partially effective in reducing the disease incidence and severity
(Wellenberg et al., 2002). The limitations with the existing vaccines have 
encouraged the development of alternative, cost effective vaccination 
strategies such as recombinant live viral vector based vaccines. Mittal et 
al. (1996) developed the first replication-competent and -defective HAd5 
carring the gD glycoprotein gene from the BHV-1 envelope. They showed 
that both forms induced immunity in cotton rats after vaccination with 107
pfu/animal in PBS and no infectious BHV-1 virions were isolated from the 
trachea of these rats after challenge. The same strategy was used with a 
rBAd3 and tested in its ability to induce mucosal and systemic immune 
response in cotton rats (Zakhartchouk et al., 1998) and calves (Reddy et 
al., 2000) with success. More recently, newborn lambs were immunized 
with 2×109 pfu/animal of replication-defective HAd5 expressing the gD 
protein of BHV-1 (Mutwiri et al., 2000). Both humoral and cell-mediated 
gD-specific mucosal immune responses were detected in 1 to 4 days old 
lambs after a single immunization and these responses were qualitatively 
and quantitatively similar to those detected in 5 to 6 weeks old lambs. 
Moreover, gD-specific maternal antibody did not significantly alter either 
mucosal or systemic gD-specific immune response. In addition, BHV-1 
glycoprotein gC was also tested in its ability to induce protective immunity 
to BHV-1 in cattle by intranasal administration of 1010 pfu/animal using a 
replication-defective HAd5 (Gogev et al., 2002). However, it was observed 
that the highest BHV-1 neutralizing antibody titers were obtained with 
rHAd5 expressing the gD protein followed by the live vaccine. 
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4.4.4. Rinderpest Virus (RPV) and Peste des Petits Ruminants Virus 
(PPRV)
Because of their high mortality and high morbidity rates, RP and PPR are 
dreaded animal diseases which are drawing back the animal production in 
many developing countries (Africa and Asia). They affect both domestic 
and wild ruminants and belong to the list A of the Office International des 
Epizooties where highly contagious animal diseases with high economic 
importance are grouped. Currently, attenuated tissue culture vaccines used 
to control RP and PPR viruses have been successfully used for many years. 
Safe and effective they provide complete and lifelong protection with a 
single subcutaneous inoculation (Yamanouchi and Barrett 1994; Diallo 
2003). However, for vaccination programs, the oral route of administration 
would be more economical. Moreover, the parenteral way of administration
means that the current vaccine cannot be used in wildlife. A production, 
purification, and encapsulation processes for a replication-defective HAd5 
expressing two different morbillivirus capsids proteins, the responsible 
agent of both diseases, is in progress. The aim is the development of heat 
stable RP/PPR oral vaccines better adapted for mass vaccination in hot 
climate developing countries. Animal vaccination and challenge testes are 
ongoing with promising preliminary results.
In summary, according to the numerous reported studies, live human or 
non human rAds, either infectious or not, appear to be attractive 
candidates for vaccination against several animal disease (Table 1.1). 
Success situations are clear against most pathogens reported and 
intermediate successes are apparent against CDV and RPV/PPRV, whereas 
vaccination against FIV have, thus far, yielded poor or inconclusive results. 
Nevertheless, this is not a comprehensive picture, since more than 50 viral 
agents of veterinary importance are known (Table 1.2).   
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Table 1.1. Host and pathogens for which Ad vaccines have been tested in 
companion animal, poultry and livestock.
Species Pathogen Protection Reference(s)
Feline FIV No (Gonin et al., 1995)
Canine CDV
RV
Partial
Yes1
(Fischer et al., 2002; Hirama et al., 
2003)
(Xiang et al., 1996; Wang et al., 1997; 
Tims et al., 2000; Vos et al., 2001)
Chicken IBV
IBDV
Yes
Yes
(Johnson et al., 2003)
(Sheppard et al., 1998)
Swine CSFV
PrV
FMDV
PRRSV
TGEV
SIV
Yes
Yes
Yes
Yes
Yes
Yes
(Hammond et al., 2000; Hammond et 
al., 2001b; Hammond et al., 2003)
(Monteil et al., 2000; Hammond et al., 
2001a)
(Mayr et al., 1999; Mayr et al., 2001; 
Moraes et al., 2002; Chinsangaram et 
al., 2003; Moraes et al., 2003; Wu et 
al., 2003)
(Gagnon et al., 2003)
(Torres et al., 1995; Torres et al., 
1996; Tuboly and Nagy 2001)
(Macklin et al., 1998; Tang et al., 
2002; Wesley et al., 2004)
Bovine BVDV
bPIV3
BHV-1
RPV / PPRV
Yes2
Yes2
Yes
Partial
(Mittal et al., 1996; Elahi et al., 
1999a; Baxi et al., 2000)
(Breker-Klassen et al., 1995)
(Mittal et al., 1996; Zakhartchouk et
al., 1998; Mutwiri et al., 2000; Reddy 
et al., 2000; Gogev et al., 2002)
Unpublished
1Obtained in mice; 2Obtained in cotton rats.
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Table 1.2.  Over 50 viral agents available in the veterinary vaccine market
Species Pathogen
Bovine Coronavirus; Foot and Mouth Disease O, A, C; Infectious 
Rhinotracheitis; Papillomavirus; Parainfluenza 3; Respiratory 
Syncytial Virus; Rotavirus; Bovine Viral Diarrhea 1 and 2
Porcine Encephalomyocarditis; Influenza; Parvovirus; Pseudorabies; 
Reproductive and Respiratory Syndrome; Rotavirus; 
Transmissible Gastroenteritis; Rabies
Equine Eastern Encephalitis; Venezuelan Encephalitis; Western 
Encephalitis; Herpesvirus 1 and 4; Influenza; Rabies
Caprine/Ovine Bluetongue; Ecthyma (Orfvirus); Rabies
Avian Encephalomyelitis; Fowl Pox; Hemorrhagic Enteritis; 
Infectious Bronchitis; Infectious Bursal Disease; 
Laryngotracheitis; Marble Spleen Disease; Marek’s Disease; 
Newcastle Disease; Paramyxovirus; Pigeon Pox; Reovirus; 
Tenosynovitis
Feline Calicivirus; Leukaemia; Panleukopenia; Peritonitis; Rabies; 
Rhinotracheitis; Lentivirus
Canine Adenovirus; Coronavirus; Distemper; Hepatitis; Measles 
Parainfluenza; Parvovirus; Rabies
5. ADENOVIRUS PRODUCTION AND PURIFICATION AS VETERINARY 
VACCINES
Process design is critical when developing cost effective veterinary 
vaccines. The goal of minimising the number of process steps is a 
prerequisite if industrial application is intended. In addition, veterinary 
vaccines do not impose the same final purity requirements as human 
vaccines, which should reflect on the purification schemes.
The production of Ad vaccines for veterinary applications is mainly based 
upon the use of continuous cell lines such as 293 (Graham et al., 1977), 
                                                                     Introduction
27
MDBK (Reddy et al., 2000; Fischer et al., 2002), VR1BL, HeLa and A549
(Zakhartchouk et al., 2003). During the cell proliferation step, various 
animal sera are used to enhance cell growth. However, supplementing cell 
culture media with such components presents several drawbacks like lot to 
lot variation, potential risk of contamination by viruses, mycoplasma, 
prions, etc. (Freshney 1986). Furthermore, regulatory authorities in Europe 
(European Medicines Agency (EMEA)) and in the United States (Food and 
Drug Administration (FDA)) have encouraged biological manufacturers to 
reduce or eliminate the use of substances of animal origin in their 
manufacturing processes. Recently, several serum and protein free culture 
media became commercially available. Although the use of such defined 
media is still expensive, the large scale production of AdV will require the 
use of this type of culture media to facilitate downstream processing and, 
in time, decrease the overall process cost. 
Figure 1.2. Bioreactors operation modes: A) Batch; B) Fed-batch; C) Perfusion; s = 
Substrate; x = Cells; F = Flow of fresh substrate; Fb = Bleed, flow of broth with cells 
out of the bioreactor; Fp = Permeate flow, cell free flow of product; VL = Working 
volume; p = Product; S0 = Substrate in the flow.
Production methods differ according to the cell type used: adherent versus
suspension cell culture. For manufacturing purposes, suspension adapted 
cell lines are more convenient for production at large scale and different 
operation modes have been developed for Ad production (Figure 1.2): i) 
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batch mode  providing the easiest way to proceed as no extra feeding is 
required and the risk of contamination is lowered given the simplicity of 
operation; ii) fed-batch mode, easy to operate and readily scalable, is 
employed to extend culture lifetime by supplementing limiting nutrients or 
reducing the accumulation of toxic metabolites; and iii) perfusion mode, 
consisting in cell retention at a relatively high concentration inside the 
bioreactor, while fresh nutrient supply and metabolite removal takes place 
(see Kamen and Henry (2004) for a review). 
Methodologies for production of concentrated AdV at low cost are 
mandatory as the market needs for Ad are increasing. Although Ad has the 
advantage to be produced at high titers (1010-1011 pfu/ml) (Babiuk and 
Tikoo 2000), to obtain a good immune response in a large proportion of 
treated animals, particularly for mucosal vaccination, large doses and thus 
culture volumes are required. Further process development aiming at 
higher yields of product is clearly necessary. Improvements in volumetric 
production can be achieved by increasing the cell density at which cells can 
be infected without lowering the specific yield of the product; however, 
production of AdV that maintain a high specific yield in batch operation is 
limited to cell densities in the range of 1×106 cell/ml; several approaches 
have been made in order to overcome this so called “cell density effect”
(Nadeau and Kamen 2003): Garnier et al. (1994) demonstrated that 
medium replacement at infection and the addition of glucose at 24 hours 
post infection (hpi) together with periodical pH adjustments, allowed a 
sustained maximum specific productivity at 1.6106 cell/ml whereas 
Nadeau et al. (1996), further improved this strategy by also adding 
essential amino acids at 24 hpi thereby stabilising volumetric productivity 
at cell densities above 2106 and below 3106 cell/ml. Such results hint at 
the existence of substrate limitation and/or byproduct inhibition at high 
cell densities. At production scale, medium exchange will increase the cost 
of the final product, which is even more critical when this is to be used in 
the veterinary field. Perfusion mode operation has been attempted as a 
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means to control the culture environment and remove toxic byproducts
(Henry et al., 2004; Kamen and Henry 2004); nevertheless, the cell specific 
productivity could only be maintained by infecting cells at densities up to 
3106 cell/ml using high perfusions rates of 2 reactor volumes per day, at 2 
days post infection, a very costly proposition (Kamen and Henry 2004).
The importance of infection kinetics on Ad production and the significance 
of variables such as Multiplicity Of Infection (MOI) and harvesting time in 
process optimisation is also mandatory to increase production yields, to 
avoid rapid depletion of costly and certified master virus banks as well as 
to ensure that the infection kinetics is reproducible between different 
production scales. Moreover, the use of low MOI at large scale would be 
preferential since an intermediate step of virus inoculum production would 
be avoided (Annex A).
Finally, veterinary products should be purified with a minimal number of 
steps and the unit operations employed should be simple and non-
expensive. Traditionally, laboratory purification of rAd was achieved using 
two rounds of cesium chloride (CsCl) density gradient ultracentrifugation. 
However, CsCl density gradient method is not scaleable. Despite the fact 
that chromatographic purification is an expensive method, ion exchange, 
hydrophobic interaction, metal chelate and size-exclusion chromatography 
have been evaluated for capture and purification of HAd5 (Huyghe et al., 
1995). Kamen and Henry (2004) developed a method for gene therapy 
application consisting of: i) harvest of infected cells by continuous 
centrifugation, ii) cell lysis by osmotic shock, iii) DNAse treatment with 
centrifugal/conditioning, iv) filtration, v) anion-exhange chromatography, 
vi) ultrafiltration/concentration and vii) size exclusion chromatography. 
This protocol allows large scale purification of AdV with purity comparable 
to the CsCl gradient method; however, it increases the final product price, 
well beyond the reach of veterinary utilisation. Introgen developed a 
method consisting of a single ion chromatography run, after 
concentration/diafiltration and nuclease treatment, with a total recovery 
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of the virus product of 70% (Zhang et al., 2001). Also, a protocol to purify 
HAd5 from the bulk harvested directly from the bioreactor after lysis 
(without a concentration step) was developed using a single ion exchange 
chromatographic step followed by ultrafiltration with a final yield of 32%
achieved in less than one working day with a minimal amount of sample 
manipulation (Peixoto et al., 2005). This process presented the advantage 
of capturing the viral particles directly from cellular extracts and to 
account for the significant amounts (25-80%) of AdV that are present in the 
culture medium at harvest time due to early cell lysis (Schagen et al., 
2000). 
6. SCOPE OF THE THESIS 
One of the mains goals of a commercial AdV cultivation process for gene 
therapy or vaccine applications is to maximise the virus volumetric 
productivity, defined as units of viral infective particles, per culture 
volume per unit time. Since one can infect at different cell concentrations, 
the cell specific productivity, defined as viral infective particles produced 
per cell and unit time, is a parallel concept; ideally, operating at the 
highest possible cell specific productivity obtained at the highest cell 
concentration at infection would maximize the volumetric productivity of 
the process but quality of the produced AdV is of paramount importance.
This thesis has attempted to improve the current manufacturing process of 
AdV production by performing infection at high cell densities maintaining 
the cell specific productivity. To achieve this, the bottlenecks in cell 
productivity have been studied as well as the parameters that may affect 
the vector production at high cell densities. The cell density at infection is 
a very important parameter as it strongly impacts the AdV volumetric 
productivity. However, in simple batch-mode operations, a relatively 
narrow range for optimal cell density at infection of 1×106 cell/ml has been 
consistently reported. The reasons for the drop in per cell productivity at 
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higher cell densities are not currently known, as medium formulations 
allow maximum cell growths reaching 8×106 cell/ml. Therefore more 
research is needed to understand and overcome this phenomenon to enable 
simple batch processes to reach higher productivities. In order to design a 
rational production process that allow the maximisation of the AdV yields 
at high cell densities, four different bioreaction approaches were explored 
in this thesis: i) media exchange, ii) refeed strategy, iii) use of non-
ammoniagenic medium and iv) cell cycle synchronisation. The knowledge 
gained in this scientific excursion is integrated into an improved process.
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Abstract
Adenoviruses are promising vectors for gene therapy and vaccination 
protocols. Consequently, the market requirements for adenovirus are 
increasing, driving the search for new methodologies for large-scale 
production of concentrated vectors with warranted purity and efficacy, in 
a cost-effective way. Nevertheless, the production of adenovirus is 
currently limited by the so-called “cell density effect”, i.e., a drop in cell 
specific productivity concomitant with increased cell concentration at 
infection. In this study, two different serum-free culture media (CD 293 
and EX-Cell) are evaluated in their effect on human 293 cells growth and 
adenovirus production at cell densities higher than 1106 cells/ml. The 
results show that EX-Cell was the better medium for cell growth. Although 
adenovirus production was equivalent in both CD 293 and EX-Cell media 
when the infection was performed at 1106 cells/ml, at 3106 cells/ml CD
293 proved to be the better medium. This result was related with the high 
ammonia content in EX-Cell medium at the highest cell concentration at 
infection.  Besides this, the large-scale production of these vectors at high 
cell densities often requires refeed strategies, which increase medium 
osmolality. While a negative effect on cell growth was observed with 
increasing osmolalities, adenovirus productivity was only affected for 
osmolalities higher than 430 mOsm.
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1. INTRODUCTION
Recombinant adenoviruses have been the vectors of choice for gene 
therapy and vaccination due to their high efficiency for gene transfer in a 
broad spectrum of cell types (Rea et al., 1999; Mountain, 2000). Therefore, 
market needs for adenovirus vectors (AdV) are constantly increasing 
causing a high demand of methodologies for the large-scale production of 
concentrated vectors with warranted levels of purity and efficacy at a low 
cost (Ferreira et al., 2005a). Different approaches for the improvement of 
production and purification processes of these viral vectors have mostly 
used serum-free media (Nadeau et al., 1996; Cote et al., 1997; Cote et al., 
1998). Serum-free media formulations are, however, more expensive than 
the traditional ones with serum supplementation and also the cell specific 
productivity decreases sharply with increased cell concentration at 
infection (CCI) above 1×106 cell/ml, the so called “cell density effect” 
(Nadeau and Kamen 2003; Kamen and Henry 2004). The reasons for such an 
effect are not very well understood but the lack of an essential nutrient or 
growth factors or high concentration of metabolic inhibitory products, 
present at high cell densities, are the most probable causes. Recently, 
several commercial serum-free media have become available; thus, one of 
the goals of this study was to evaluate the effect of two different 
commercially available serum-free media on human 293 cell growth and 
AdV productivity at high cell densities.
Besides culture media composition and the accumulation of inhibitory 
byproducts, several other factors have been reported to influence cell 
growth and AdV productivity, namely the vector itself, the cell line, the 
pH, pCO2 and temperature (Eloit and Adam 1995; Iyer et al., 1999; Jardon 
and Garnier 2003; Nadeau and Kamen 2003). Due to the common need to 
implement refeeding strategies for AdV production, it is pertinent to 
determine if the consequent increase in osmolality has an influence on cell 
growth and AdV productivity. Only one study has reported the influence of 
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osmolality on protein production by human 293 cells (Nadeau et al., 1996), 
resulting in increased productions at high osmolalities (500 mOsm). 
Nevertheless, the effect of osmolality on viral productivity has not been 
assessed yet, thus this study reports effect of osmolality upon human 293 
cell growth and AdV productivity. 
2. MATERIALS AND METHODS
2.1. Cell line and culture conditions
Suspension-adapted human 293 cells (ATCC-CRL-1573) were grown in 125 
ml Erlenmeyer flaks, with 40 ml medium in two different serum free 
media: CD 293, a protein-free medium from Invitrogen and EX-Cell, an 
animal-protein free medium from JRH, all supplemented with 6 mM 
glutamine from Invitrogen. Cells were incubated at 37 ºC in a humidified 
atmosphere of 8 and 10 % of CO2 in air, respectively (in order to obtain an 
equal pH in each medium), with a cell inoculum of 0.25×106 cell/ml. 
Regarding the osmolality studies, five different osmolalities were 
evaluated: 230, 330, 380, 430 and 480 mOsm. The osmolality of the 
medium was increased by addition of a 1 M NaCl.
2.2. Infection in shake flasks
A replication-defective AdV derived from type 5 AdV was kindly provided by 
Dr. Tom Barret (Institute for Animal Health-Pirbright, UK). Infection was 
made when the cells reached a concentration of 1×106 cell/ml using a 
multiplicity of infection (MOI) of 10 (see annex A). Infection was also made 
when cells reached a concentration of 2×106 cell/ml and 3×106 cell/ml for 
the studies on media effect, maintaining the same MOI. Infected human 
293 cells were harvested at 48 h post infection (hpi), determined as the 
optimal harvest time (Annex A).
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2.3. Virus culture samples preparation
Infected human 293 cells were harvested at 48 hpi and centrifuged at 1000 
g for 10 min at 4 ºC; the resulting cell supernatant was distributed into 
small aliquots and stored at -85 ºC for the evaluation of extracellular virus; 
the resulting cell pellet was resuspended in a known volume of lysing 
buffer (Tris/HCl 10 mM, pH 8.0, 2mM MgCl2 and 0.1% Triton-X 100) and the 
cells were disrupted by 1 minute vortex. Cell debris was removed by 
centrifugation at 3000 g for 10 min at 4 ºC and the resulting cell lysate 
supernatant was distributed into small aliquots and stored at –85 ºC for
quantification of intracellular viruses content.
2.4. Analytical Methods
Cell concentration and viability were determined by counting the cells on a 
haemacytometer using the Trypan Blue dye exclusion method.
AdV titration was performed by the end-point dilution method using 96 well 
plates and human 293 cells. Infectious particles (ip) in 50 % tissue culture 
infective dose (TCID50) were determined according to the statistical 
method of Spearman-Karber (Darling et al., 1998).
Ammonia was quantified enzymatically using a UV-test Cat. No. 
1112732035 (Boehringer Mannheim, R-Biopharm AG)
Osmolality was measured in a Digital Micro Osmometer Type 5R from 
Hermann Roebling MESSTECHNIK, Germany.
3. RESULTS AND DISCUSSION
3.1. Effect of media on cell growth
In order to obtain high cell yields for AdV production, two different serum-
free media were tested in their ability to grow human 293 cells. As shown 
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in Figure 2.1, EX-Cell allowed a maximum cell number of 7.5×106 cell/ml, 
while the maximum cell number obtained in CD 293 was approximately 
4×106 cell/ml, attained at similar specific growth rates (0.018 h-1 and 0.019 
h-1 for CD 293 and EX-Cell, respectively). Despite the fact that EX-Cell has a 
higher glucose concentration (30 mM) than CD 293 (25 mM), the main 
difference observed between the two media composition is in the amino 
acids concentration. By following amino acid consumption it was seen that 
threonine was the unique amino acid that was completely consumed when 
cells reached 4×106 cell/ml in CD 293 (data not shown). Furthermore, EX-
Cell contains a concentration of threonine 10 times higher than CD 293, 
and the refeeding of this amino acid in CD 293 led to an increase in 
maximum viable cell concentration to 5.5×106 cell/ml (data not shown).
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Figure 2.1. Growth curves of human 293 cells obtained in two different culture 
media: (o) CD 293 and (□) EX-Cell.
3.2. Effect of media on AdV productivity
Since EX-Cell medium allowed the higher maximum cell density, the effect 
upon AdV productivity at high CCI was evaluated and compared with CD
293 medium. As shown in Figure 2.2, when a CCI of 1×106 cell/ml was used, 
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both culture media were similar in their ability to “support” AdV 
production. The specific productivity in human 293 cells using CD 293 
medium was not significantly affected when a CCI of 2×106 cell/ml was 
used, while a 10 fold decrease was observed when EX-Cell medium was 
used. For a CCI of 3×106 cell/ml no effective AdV production was observed 
for EX-Cell, and for CD 293 a 1 log decrease (as compared with CCI of 1×106
cell/ml) was observed, confirming the CD 293 medium as a good choice for 
AdV production at high cell densities (Ferreira et al., 2005b).
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Figure 2.2. Cell specific productivity in CD 293 (■) and EX-Cell (□) at CCIs of 1, 2 
and 3×106 cell/ml. Error bars represent the propagated error considering one SD of 
quadruplicate sample assay for two samples.
The decrease in cell specific productivity obtained at a CCI of 3×106 cell/ml 
in CD 293 and EX-Cell media might be due to the lack of an essential 
nutrient or growth factors or to the byproducts accumulation. As stated in 
Chapter III, Part 1, glutamine, threonine and glucose are limiting nutrients 
in CD 293 medium at CCI of 3×106 cell/ml, although no improvement on 
AdV productivity was achieved after the addition of these nutrients at the 
time of infection; on the other hand, ammonia was at an inhibitory 
concentration for infection at this CCI. In this present study, following 
ammonia production for both media, it was observed that at 3×106 cell/ml 
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ammonia concentration was 1.8 times higher in EX-Cell medium than in CD
293 (Figure 2.3), supporting that ammonia is one of the main contributor 
for the “cell density effect”. 
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Figure 2.3. Ammonia production (full lines) during cell growth (broken lines) in CD
293 (●, ○) and in EX-Cell (■, □). 
3.3. Effect of osmolality increase on cell growth and AdV productivity
The effect of increasing osmolality on human 293 cell growth was 
evaluated by increasing it to 330, 380, 430 and 480 mOsm from original 
values of 230 mOsm at the inoculation time and when the cells reached a 
concentration of 1×106 cell/ml (concentration where the cell specific 
productivity is maximal). As shown in Table 2.1, decreases on specific 
growth rate and maximum viable cell concentration were observed when 
the osmolality was increased at the innoculation time, leading to growth 
inhibition at the maximum osmolality studied (480 mOsm), whereas 
osmolality increases at 1×106 cell/ml had a lesser effect upon both specific 
growth rate and maximum viable cell concentration.
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Table 1.1. Specific growth rates (and maximum viable cell concentration 
(Xmax) obtained at different osmolalities. 
 (h-1)
Xmax
(106 cell/ml)
Control 0.019 + 0.001 3.81  +  0.19
At inoculation time
330i 0.018 + 0.001 2.81  +  0.14
380i 0.013 + 0.001 2.18  +  0.11
430i 0.009 + 0.001 0.94  +  0.05
480i - -
At 1×106 cell/ml
330m 0.015 + 0.001 3.08  +  0.15
380m 0.011 + 0.001 3.20  +  0.16
430m 0.009 + 0.001 2.23  +  0.11
480m 0.004 + 0.001 1.61  +  0.08
i- osmolality increased at inoculation time;
m- osmolality increased when the cells reached 1×106 cell/ml.
The effect of increasing osmolality on AdV productivity at a cell 
concentration of 1×106 cell/ml was evaluated by increasing the osmolality 
at the inoculation time or at the infection time. The infection of the cells 
with an increased initial osmolality of 430 mOsm and 480 mOsm was not 
evaluated because the cells did not reach the concentration of 1×106
cell/ml. As shown in Figure 2.4, osmolality values up to 430 mOsm did not 
affect AdV productivity but an increase in osmolality for 480 mOsm at 
infection time caused a reduction on cell specific productivity of two 
orders of magnitude. 
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Figure 2.4. Cell specific productivity obtained at infection at a CCI of 1×106
cell/ml, after increases in osmolality. i: at inoculation time; m: when the cells 
reached 1×106 cell/ml. Error bars represent the propagated error considering one 
SD of quadruplicate sample assay for two samples.
From the data obtained in this work it can be concluded that CD 293 
medium is the better medium for AdV production in human 293 cells at 
high CCI when compared with EX-Cell medium. Possibly the main reason for 
such a result is the higher ammonia production registered in EX-Cell 
medium. It can also be concluded that increases in osmolality at the time 
of infection do not have any negative effect in terms of cell growth and 
AdV productivity as long as osmolality after infection is kept below 430 
mOsm. Thus, fed-batch supplementation during the growth and production 
phases does not have any effect in terms of osmolality, since such values 
are difficult to achieve. Moreover, contrary to the increase in PTP1C 
protein production observed by Nadeau et al. (1996) on these cells with 
increased osmolality obtained by NaCl addition, in this work the cell 
specific productivity was not enhanced. Furthermore, the addition of NaCl 
may affect cell behaviour, since the imbalance in osmotic pressure 
increase the uptake of Na+ and, consequently, alter cell metabolism. 
However, also in this case, no effect on AdV productivities was registered.
Chapter II
56
4. ACKNOWLEDGEMENT
The authors are grateful to Dr Tom Barret (Institute for Animal Health -
Pirbright, UK) for providing the recombinant adenovirus. The authors 
acknowledge the financial support received from the European Commission 
(Project ICF599A4PR01) and from Fundação para a Ciência e Tecnologia –
Portugal (Project POCTI/BIO/46515/2002 and student grant 
SFRH/BD/10614/2002).
                                                                Cell Density Effect
57
5. REFERENCES
Cote, J., Bourget, L., Garnier, A. and Kamen, A., 1997. Study of adenovirus 
production in serum-free 293SF suspension culture by GFP-expression monitoring. 
Biotechnol Prog 13, 709-14.
Cote, J., Garnier, A., Massie, B. and Kamen, A., 1998. Serum-free production of 
recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 
59, 567-75.
Darling, A.J., Boose, J.A. and Spaltro, J., 1998. Virus assay methods: accuracy and 
validation. Biologicals 26, 105-10.
Eloit, M. and Adam, M., 1995. Isogenic adenoviruses type 5 expressing or not 
expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive 
and non-permissive species. J Gen Virol 76, 1583-1589.
Ferreira, T.B., Alves, P.M., Aunins, J.G. and Carrondo, M.J.T., 2005a. Use of 
adenoviral vectors as veterinary vaccines. Gene Ther 12 Suppl 1, S73-83.
Ferreira, T.B., Ferreira, A.L., Carrondo, M.J.T. and Alves, P.M., 2005b. Effect of 
refeed strategies and non-ammoniagenic medium on adenovirus production at high 
cell densities. J Biotechnol 119, 272-80.
Iyer, P., Ostrove, J.M. and Vacante, D., 1999. Comparison of manufacturing 
techniques for adenovirus production. Cytotechnology 30, 169-172.
Jardon, M. and Garnier, A., 2003. pH, pCO2, and Temperature Effect on R-
Adenovirus Production. Biotechnol Prog 19, 202-208.
Kamen, A. and Henry, O., 2004. Development and optimization of an adenovirus 
production process. J Gene Med 6 Suppl 1, S184-192.
Mountain, A., 2000. Gene therapy: the first decade. Trends Biotechnol 18, 119-128.
Nadeau, I., Garnier, A., Côté, J., Massie, B., Chavarie, C. and Kamen, A., 1996. 
Improvement of recombinant protein production with human adenovirus/293S 
expression system using fed-batch Strategies. Biotechnol Bioeng 51, 613-623.
Chapter II
58
Nadeau, I. and Kamen, A., 2003. Production of adenovirus vector for gene therapy. 
Biotechnol Adv 20, 475-489.
Rea, D., Schagen, F.H., Hoeben, R.C., Mehtali, M., Havenga, M.J., Toes, R.E., 
Melief, C.J. and Offringa, R., 1999. Adenoviruses activate human dendritic cells 
without polarization toward a T-helper type 1-inducing subset. J Virol 73, 10245-
10253.
CHAPTER III
Medium Limitations

                                    Refeed strategies and non-ammoniagenic medium
61
PART 1
Effect of refeed strategies and non-ammoniagenic medium on 
adenovirus production at high cell densities
Ferreira T.B., Ferreira A.L., Carrondo M.J.T., Alves P.M. (2005) J. 
Biotechnol., 119:272-280.
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Abstract
Recombinant adenoviruses became one of the vectors of choice for delivery 
and expression of foreign proteins for gene therapy and vaccination 
purposes. Nevertheless, the production of adenovirus is currently limited 
by the so-called “cell density effect”, i.e., a drop in cell specific 
productivity concomitant with increased cell concentration at infection 
(CCI).
This work describes the characterisation and optimisation of the infection 
process in order to improve recombinant adenovirus type 5 yields at high 
cell densities. For that purpose, 293 cells adapted to suspension were 
grown in 2 L bioreactors and infected at different cell concentrations, 
using different refeed strategies, while evaluating cell metabolism. The 
consumption of amino acids is enhanced during infection, although no 
amino acid limitation was detected for cells infected at concentrations in 
the range of 2106 cell/ml, for which the highest volumetric productivity
was obtained in batch mode. Conversely, infecting at cell concentrations in 
the range of 3106 cell/ml led to complete depletion of glucose, glutamine 
and threonine before the optimal harvesting time, a significant decrease in 
volumetric productivity being observed; the effect of amino acids and 
glucose addition at infection time on cell specific and volumetric 
productivity of adenovirus was assessed, no improvement on adenovirus 
production being achieved. The effect of ammonia, present in high 
concentrations at 3106 cell/ml, was evaluated and seem to be 
detrimental; an 1.8 fold increase on adenovirus volumetric productivity 
was obtained for infections performed at 3106 cell/ml when non-
ammoniagenic medium was used.
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1. INTRODUCTION
Delivery of genes to somatic tissue for the prevention and treatment of a 
wide range of genetic and acquired diseases is a promising route for 
therapy. The added genes can provide a missing function, modulate the 
immune response or initiate cell suicide in the presence of certain drugs. 
Since recombinant adenoviruses (AdV) are highly efficient at gene transfer 
for a broad spectrum of cell types and species they became one of the 
vectors of choice for gene delivery and expression of foreign proteins in 
gene therapy and vaccination (Rea et al., 1999; Mountain 2000). 
Consequently, the market requirements for AdV are increasing, driving the 
search for new methodologies for large scale production of concentrated 
vectors with warranted purity and efficacy. 
Different approaches for the improvement of production and purification 
processes of these viral vectors have been reported (Huyghe et al., 1995; 
Nadeau et al., 1996; Iyer et al., 1999; Blanche et al., 2000). Factors such 
as the construction of the vector itself, the host cell line and the culture 
medium can affect AdV production rates (Eloit and Adam 1995; Iyer et al., 
1999; Nadeau and Kamen 2003). Effects of pH, pCO2 and temperature on 
AdV production have also been reported (Xie et al., 2002; Jardon and 
Garnier 2003). Currently, AdV production at high cell specific productivity 
is limited to low cell densities, in the range of 1106 cell/ml (Kamen and 
Henry 2004). This “cell density effect” has been considered by several 
authors as a consequence of nutrient limitations or accumulation of 
byproducts. The understanding of these limiting factors will contribute to 
design a robust and cheap process for AdV production at high cell densities, 
by adding the essential nutrients or using a new medium formulation that 
allows the infection at higher cell densities maintaining the specific cell 
productivity. Although metabolic flux analysis has been used to 
characterize the effect upon cell metabolism of various environmental 
conditions the nature of the factors limiting AdV productivities at high cell 
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densities remains unknown (Nadeau et al., 2000a; Nadeau et al., 2000b; 
Nadeau et al., 2002).
Different strategies for improvement have been proposed: Garnier et al. 
(1994) demonstrated that medium replacement at 0 hours post infection 
(hpi) and the addition of glucose at 24 hpi together with periodical pH 
adjustments, allowed a sustained maximum cell specific productivity at 
1.6106 cell/ml whereas, Nadeau et al. (1996) further improved this 
strategy by also adding essential amino acids at 24 hpi thereby stabilising 
AdV volumetric productivity at cell densities just above 2106 cell/ml. At 
production scale, medium exchange will increase the cost of the final 
product, which is even more critical when the final product is to be used in 
the veterinary field. Perfusion mode operation has been attempted as a 
means to control the culture environment and remove toxic byproducts 
(Henry et al., 2004; Kamen and Henry 2004); nevertheless, the cell specific 
productivity could only be maintained by infecting cells at densities up to 
3106 cell/ml using high perfusions rates of 2 reactor volumes per day, at 2 
days post infection, a very costly proposition. 
The accumulation of ammonia and lactate, major products from glutamine 
and glucose metabolism, has been demonstrated to diminish mammalian 
cell growth and influence cell metabolism and protein productivity (Cruz et 
al., 2000). Attempts have been made to control cell metabolism and 
reduce the production of these metabolites, such as: i) maintaining low 
concentrations of glucose and glutamine to shift cell metabolism towards 
more efficient states (Cruz et al., 1999), or ii) adapting the cells to grow in 
media with other carbon and nitrogen sources like galactose and glutamate 
(Altamirano et al., 2000). Specifically, for 293 cells often utilised for AdV 
production, lactate at 20 mM reduced cell viability to 50% with a much 
reduced effect on product, whereas ammonia at 1 mM already inhibited 
cell growth; under these conditions the effects upon AdV production were 
not identified (Nadeau et al., 1996).
In this work, factors limiting the AdV production at high cell densities were 
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investigated. Refeed strategies and the adaptation to non-ammoniagenic 
media were evaluated in order to understand the metabolic requirements 
when infection is done at high cell densities and to overcome the so called 
"cell density effect", thus permitting the achievement of higher volumetric 
productivities for AdV. A first generation AdV vector was employed.
2. MATERIALS AND METHODS
2.1. Cell line and medium
293 cells, purchased from ATCC (ATCC-CRL-1573), were adapted to 
suspension and grown in commercially available serum and protein free 
medium, CD 293, supplemented with 4 mM of glutamine (all from 
Invitrogen, Glasgow, UK) at a humidified atmosphere of 8% CO2 in air at 
37ºC in shake flasks (corning, NY). Cells were routinely propagated twice a 
week with an inoculum of 0.5×106 cell/ml.
2.2. Infection in shake flasks
Infection was performed in 125 ml shake flasks with final volumes of 40 ml 
in a humidified atmosphere of 8% CO2 in air at 37ºC. All the infections were 
done using a multiplicity of infection (MOI) of 10 and AdV harvested at 48 
hpi (see Annex A).
2.3. Stirred tank studies
Bioreaction studies were performed in a 2 L bioreactor (Braun, Melsungen, 
Germany). The agitation rate was maintained at 110 rpm (NRe = 6800); pH 
was controlled at 7.2 by aeration with a CO2 gas-mixture and NaOH 0.2 M; 
the dissolved oxygen was controlled at 80% air saturation. All the infections 
were done using a MOI of 10 and AdV harvested at 48 hpi (see Annex A). For 
                                    Refeed strategies and non-ammoniagenic medium
67
the fed-batch operation mode, threonine, glutamate, amino acids cocktail 
(RPMI 1640 50) (all from Sigma-Aldrich, St. Louis, MO), glutamine and 
glucose (Merck, Darmstadt, Germany) solutions were used.
2.4. Virus culture samples preparation
A replication-defective AdV derived from type 5 AdV was kindly provided by 
Dr. Tom Barret (IAH-Pirbright, UK). Infected 293 cells were harvested at 48 
hpi and centrifuged at 1000g for 10 min. at 4ºC. The resulting cell 
supernatant was distributed into small aliquots and stored at -85ºC for the 
evaluation of extracellular virus. The resulting cell pellet was resuspended 
in a known volume of Tris buffer 10 mM, pH 8.0 supplemented with 2 mM 
MgCl2 and 0.1% Triton. Cells were disrupted by vortexing for 1 minute and 
cell debris removed by centrifugation at 3000g for 10 min. at 4ºC. The 
resulting cell lysate supernatant was dispensed into small aliquots and 
stored at -85ºC for quantification of intracellular viral content.
2.5. Analytical Methods
Cell concentration and viability were determined by counting cells on a
Fuchs-Rosenthal haemocytometer (Brand, Wertheim, Germany) using the 
trypan blue (Invitrogen) dye exclusion method.
AV titration was performed by the end-point dilution method (TCID50) using 
96 well plates and 293 cells. The titer was determined according to the 
method of Spearman and Kraber, as described elsewhere (Darling et al., 
1998).
Glucose and lactate were analyzed using a YSI Multiparameter Bioanalytical 
System Model 7100 MBS (Yellow Springs, USA).
Ammonia was quantified enzymatically using a UV test number 1112732035 
(Boehringer Mannheim, R-Biopharm AG, Germany).
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Complete analysis of amino acid composition was done by HPLC using a 
Pico-Tag (Waters) system. Amino acids were derivatized with the phenyl-
isothiocianate method (Matsudaira 1990). The Pico-Tag system consisted of 
a Nova-Pak C18 column (WAT 011695), a Waters 510 pump, and automatic 
injector Waters 717 and a tunable Absorbance Detector 486. Data 
acquisition was performed on a PC using software from Millenium.
3. RESULTS AND DISCUSSION
3.1. Effect of CCI on AdV production
The effect of CCI on the final AdV production yields was evaluated in 2 L 
bioreactor. Infection at CCI 1106 cell/ml (control), 2106 cell/ml and 
3106 cell/ml with or without complete media exchange at the time of 
infection was compared (Fig. 3.1.1). As can be observed, cell specific 
productivity is not significantly affected at CCI 2106 cell/ml, when 
compared with the control, leading to a 1.3 fold increase on AdV 
volumetric productivity.  However, one log decrease on cell specific 
productivity was observed at CCI 3106 cell/ml.
Medium exchange at the time of infection and the addition of glucose and 
essential amino acids at 24 hpi has been reported to allow a sustained 
maximum specific productivity just above 2106 cell/ml (Nadeau et al., 
1996). Figure 3.1.1 shows that a single medium exchange at the time of 
infection is enough to maintain the cell specific productivity at the 
maximum CCI of 3106 cell/ml, for which the highest volumetric 
productivity was obtained. The results obtained are improvements on those 
reported in the literature, suggesting the serum and protein free medium 
used in this study (CD 293) to be a good choice for AdV production at high 
cell densities. Nevertheless, at production scale, a medium exchange could 
make the final product cost prohibitive. To determine how these results 
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are related to the metabolism of the cells, the kinetics of nutrient 
consumption and metabolite production were evaluated.
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Figure 3.1.1. Effect of media exchange and CCI in cell specific ( ) and AdV 
volumetric ( ) productivities. CCI 1, CCI 2 and CCI 3 correspond to 1, 2 and 3106
cell/ml at time of infection, respectively.
3.2. Cell metabolism evaluation at different CCIs
Cell metabolism was assessed before and after infection at CCI 1106
cell/ml and 3106 cell/ml. After infection at CCI 1106 cell/ml, increases 
of 1.3 fold in glutamine and 1.8 fold in glucose specific consumption rates 
were observed, concomitant with increases of 1.2 fold in ammonia and 3.9 
fold in lactate specific production rates (data not shown). No significant 
alteration in the molar ratio of ammonia produced/glutamine consumed 
was observed, whereas the molar ratio of lactate produced/glucose 
consumed increased 2.3 times (Table 3.1.1). Elias et al. (2003) observed 
that for 293 cells, the flux of glucose into the TCA cycle and its subsequent 
utilization is limited as a result of the lack of certain key enzymes in this 
pathway. This may be the explanation for the significant increase in the 
molar ratio of lactate produced/glucose consumed observed in our 
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experiments, since after infection the glucose uptake increases as a result 
of energy requirements; however, the flux of glucose into the TCA cycle 
seems limited as the fermentation takes place, leading to lactate 
accumulation.
Table 3.1.1. Molar ratios of ammonia produced/glutamine consumed and lactate 
produced/glucose consumed in non infected cells, cells infected at CCI 1106
cell/ml and CCI 3106 cells/ml.
Non infected CCI 1 CCI 3
Yammonia/glutamine 0.67 0.59 0.30
Ylactate/glucose 0.78 1.83 0.50
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Figure 3.1.2. Effect of infection and CCI in amino acid metabolism. The bar 
correspond to specific consumption and production rates of amino acids in non 
infected cells ( ), cells infected at CCI 1 ( ) and 3106 cell/ml ( ).
For almost all amino acids, increases in specific consumption and 
production rates were observed after infection at CCI 1106 cell/ml (Fig. 
3.1.2). However, when the infection was performed at CCI 3106 cell/ml, a 
decrease in amino acids specific consumption rates was observed while 
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some of the usually produced amino acids started to be consumed. 
Moreover, significant decreases in glucose specific consumption rate, as 
well as in ammonia and lactate specific production rates, were observed 
for the infection at this CCI (data not shown). Following the decay in cell 
viability after infection (Fig. 3.1.3) a significant decrease was observed at 
24 hpi for CCI 3106 cell/ml, while at CCI 1106 cell/ml only after 72 hpi 
the cell decay becomes apparent, this being the time, according to the 
literature, corresponding to an infection cycle (Nadeau and Kamen 2003). 
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Figure 3.1.3. Effect of CCI in cell viability (full symbols) and in AdV productivity 
(empty symbols). CCI 1106 cell/ml are represented as triangles and CCI 3106
cell/ml as circles. 
Figure 3.1.3 confirms cell specific production rate to be lower at CCI 3106
cell/ml, as expected. These results support the claim that the “cell density 
effect” is a consequence of nutrient limitations or accumulation of 
byproducts. Moreover the consumption of the amino acids that are usually 
produced is a means for the cells to balance the lack of nutrients. From the 
analysed nutrients, it was observed that glutamine, threonine and glucose 
are totally consumed before the optimal harvesting time that corresponds 
to 48 hpi (Fig. 3.1.4); however, the decrease in the metabolic activity 
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started at the time of infection and so did the AdV productivity. It can be 
further observed that lactate and ammonia concentrations were high at the 
time of infection: 17.4 mM and 1.5 mM, increasing to 22 mM and 1.8 mM, 
respectively, at 48 hpi. Thus, limitation of nutrients together with a toxic 
effect promoted by the accumulation of byproducts seems responsible for 
the significant decrease on AdV production yields observed at the highest 
CCI.
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Figure 3.1.4. (A) Glutamine (Gln) ( ) and threonine (Thr) ( ) consumption and 
(B) glucose (Glc) ( ) consumption and lactate (Lac) ( ) and ammonia ( ) 
production after infection at CCI 3106 cell/ml. 4.0, 0.5 and 25.0 mM (maximum 
value of y axis scale) are the initial medium concentration for glutamine, threonine 
and glucose respectively.
3.3. AdV production with a refeed strategy
Since glutamine, threonine and glucose were found to be limiting nutrients 
at CCI 3106 cell/ml, two different fed-batch operation modes were tested 
with the addition of either (1) threonine, glutamine and glucose or (2) an 
amino acid cocktail and glucose at the time of infection; both were 
compared against a batch control mode (Fig. 3.1.5). Surprisingly, no 
improvement on cell specific and AdV volumetric productivities was 
obtained for either strategy. A significant increase on ammonia 
accumulation for both strategies was observed, when compared with the 
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batch control, associated with the glutamine addition (data not shown). 
These results confirm that glutamine, threonine and glucose limitation are 
not the only limiting factors on AdV production, since the refeeding of 
these nutrients was not enough to improve AdV production yields at CCI 
3106 cell/ml.
1E+01
1E+02
1E+03
1E+04
1E+08
1E+09
1E+10
1E+11
CCI 1 CCI 3+
Glc+Gln
+Thr
CCI 3+
Glc+a.a.
CCI 3
ip
/c
el
l
ip
/m
l
ip
/c
el
l
ip
/m
l
Figure 3.1.5. Effect of refeed strategies in cell specific ( ) and AdV volumetric 
( ) productivities. CCI 1 and CCI 3 correspond to 1 and 3106 cell/ml at time of 
infection, respectively. Fed-batch operations modes were performed with glucose 
(Glc), glutamine (gln) and threonine (thr) or Glc and amino acids cocktail (a.a.) 
refeed at the time of infection.
3.4. AdV production in non-ammoniagenic media
Table 3.1.2. Specific growth rates () and maximum total cell number (Xmax) 
obtained for cells growing in glutamine supplemented medium and in non 
ammoniagenic medium.
Glutamine Non-ammoniagenic
 (h-1) 0.018 0.014
Xmax (cell/ml) 5.5×106 4.5×106
An important evidence from this study was the high ammonia 
concentration observed at CCI 3106 cell/ml (1.5 mM) (Fig. 3.1.4), 
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considered toxic for cell growth (Nadeau et al., 1996); however the toxic 
effect of this byproduct on AdV production is not known.
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Figure 3.1.6. Cell specific consumption and production rates of amino acids in cells 
growing in glutamine supplemented medium ( ) and non-ammoniagenic medium 
( ).
Ammonia was shown to induce cytoplasm acidification which can affect 
AdV stability (McQueen and Bailey 1991). Thus, in order to understand the 
effect of this byproduct on AdV production yields, 293 cells were adapted 
to grow in CD 293 medium in which glutamine was replaced by glutamate 
(from now on referred as non-ammoniagenic medium). As for other cell 
lines (Christie and Butler 1999), a prolonged lag phase, reduced growth 
rates and lower maximum cell densities were observed (Table 3.1.2). As 
expected, ammonia specific production rate was significantly reduced, 
from 4×10-9 mmol/cell.h for cells grown in glutamine supplemented 
medium to 0.09×10-9 mmol/cell.h for cells growing in non-ammoniagenic 
medium; an increase in all amino acids specific consumption rate was also 
observed, particularly glutamate, which is produced in cells growing in 
glutamine supplemented media, and serine (Fig. 3.1.6). Furthermore, it 
was observed that the increase in threonine specific consumption rate led 
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to the depletion of this amino acid and a refeed had to be done at 2×106
cell/ml. Comparing with glutamine supplemented medium, no significant 
variations were observed in glucose specific consumption and lactate 
production rates for non infected cells.
Table 3.1.3. Molar ratios of lactate produced/glucose consumed in non infected 
cells, cells infected at CCI 1106 cell/ml and CCI 3106 cells/ml for 293 cells 
adapted to non-ammoniagenic medium.
Non infected CCI 1 CCI 3
Ylactate/glucose 0.73 1.42 0.55
293 cells adapted to non-ammoniagenic medium were infected at CCI 1106
cell/ml and CCI 3106 cell/ml. After infection at CCI 1106 cell/ml, while 
glucose specific consumption rate increased 1.3 times, an increase of 2 
fold in lactate specific production rate was observed (data not shown). It 
seems that glucose was used in a more energetic way, since the molar ratio 
of lactate produced/glucose consumed increased 1.9 times (Table 3.1.3), 
less than the observed value when glutamine containing medium was used, 
and less lactate was accumulated. Comparing with infection of cells 
growing in glutamine supplemented medium, 1.8 times higher AdV 
volumetric productivities were observed at CCI 3×106 cell/ml than at CCI 
1×106 cell/ml (Fig. 3.1.7); although there was a drop of the cell specific 
productivity, this was not so significant as the corresponding drop for 
glutamine containing medium, being 39% and 88% respectively. The final 
ammonia concentration was approximately 10 times lower at the highest 
CCI for the non-ammoniagenic medium than that observed for the 
glutamine supplemented medium, at 0.2 mM and 2 mM respectively; also 
the final lactate concentration was 1.8 times lower (12 mM) when the 
infection was performed in the non-ammoniagenic medium at the highest 
CCI, below to the reported toxic concentrations (data not shown).
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Figure 3.1.7. Effect of medium supplement in cell specific ( ) and AdV volumetric 
( ) productivities. Gln and Glu correspond to glutamine and glutamate 
supplemented medium and CCI 1 and CCI 3 correspond to 1 and 3106 cell/ml at 
time of infection, respectively.
These results suggest an inhibitory effect on AdV production by ammonia 
accumulation and confirmed that the use of non-ammoniagenic medium 
improved AdV volumetric productivity. However, the ammonia 
accumulation seems not to be the only inhibitory factor on AdV production, 
since in optimal condition, a 3 times increase on AdV volumetric 
productivity was to be expected at CCI 3×106 cell/ml, when only an 1.8 
fold increase was obtained, corresponding to the highest decrease in cell 
specific productivity indicated above.
4. CONCLUSIONS
The present study shows that by using CD 293 medium the AdV production 
reaches the highest volumetric productivity reported for an infection 
performed at CCI of 2106 cell/ml in batch mode. Moreover, AdV 
productivity can be improved even at a CCI of 3106 cell/ml with a single 
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CD 293 medium exchange at the time of infection. Nevertheless, for scaled 
up processes, a medium exchange step is not cost effective. 
Glutamine, threonine and glucose were found to be limiting nutrients at 
CCI of 3106 cell/ml, although no improvement on AdV productivity could 
be achieved after the addition of these nutrients at the time of infection. 
On the other hand, ammonia was at an inhibitory concentration for 
infection at this CCI. By adapting the cells to non-ammoniagenic medium, 
an 1.8 fold increase in AdV volumetric productivity at CCI 3106 cell/ml 
was obtained, although the “ideal” situation would have been an increase 
of 3 times at this CCI; thus, ammonia is an important parameter to be 
considered for infection at high cell densities, but not the only. 
Future improvements to the culture process may come from analysis of 
other nutrients than the usual glucose, lactate, ammonia and amino acids. 
A cocktail of different nutrients are present in the culture media that may 
have an important impact on AdV production as vitamins, lipids, hormones 
and growth factors (see Annex B). Combination of these measurements may 
lead to the design of a new strategy permitting a higher cell specific and, 
consequently, AdV volumetric productivity.
5. ACKNOWLEDGEMENT
The authors are grateful to Dr Tom Barret (IAH-Pirbright, UK) for providing 
the recombinant adenovirus and Eng Paula Chicau for providing data from 
the amino acids analysis service at the Instituto de Tecnologia Química e 
Biológica, Universidade Nova de Lisboa, Oeiras, Portugal. The authors 
acknowledge and appreciate the financial support received from the 
European Commission (Project ICF599A4PR01) and from Fundação para a 
Ciência e Tecnologia – Portugal (Project POCTI/BIO/46515/2002 and 
student grant SFRH/BD/10614/2002).
Chapter III.1
78
6. REFERENCES
Altamirano, C., Paredes, C., Cairo, J.J. and Godia, F., 2000. Improvement of CHO 
cell culture medium formulation: simultaneous substitution of glucose and 
glutamine. Biotechnol Prog 16, 69-75.
Blanche, F., Cameron, B., Barbot, A., Ferrero, L., Guillemin, T., Guyot, S., 
Somarriba, S. and Bisch, D., 2000. An improved anion-exchange HPLC method for 
the detection and purification of adenoviral particles. Gene Ther 7, 1055-1062.
Christie, A. and Butler, M., 1999. The adaptation of BHK cells to a non-
ammoniagenic glutamate-based culture medium. Biotechnol Bioeng 64, 298-309.
Cruz, H.J., Ferreira, A.S., Freitas, C.M., Moreira, J.L. and Carrondo, M.J., 1999. 
Metabolic responses to different glucose and glutamine levels in baby hamster 
kidney cell culture. Appl Microbiol Biotechnol 51, 579-585.
Cruz, H.J., Freitas, C.M., Alves, P.M., Moreira, J.L. and Carrondo, M.J., 2000. 
Effects of ammonia and lactate on growth, metabolism, and productivity of BHK 
cells. Enzyme Microb Technol 27, 43-52.
Darling, A.J., Boose, J.A. and Spaltro, J., 1998. Virus assay methods: accuracy and 
validation. Biologicals 26, 105-10.
Elias, C.B., Carpentier, E., Durocher, Y., Bisson, L., Wagner, R. and Kamen, A., 
2003. Improving glucose and glutamine metabolism of human HEK 293 and 
Trichoplusia ni insect cells engineered to express a cytosolic pyruvate carboxylase 
enzyme. Biotechnol Prog 19, 90-97.
Eloit, M. and Adam, M., 1995. Isogenic adenoviruses type 5 expressing or not 
expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive 
and non-permissive species. J Gen Virol 76, 1583-1589.
Garnier, A., Cote, J., Nadeau, I., Kamen, A. and Massie, B., 1994. Scale-up of the 
adenovirus expression system for the production of recombinant protein in human 
293S cells. Cytotechnology 15, 145-155.
                                    Refeed strategies and non-ammoniagenic medium
79
Henry, O., Dormond, E., Perrier, M. and Kamen, A., 2004. Insights into adenoviral 
vector production kinetics in acoustic filter-based perfusion cultures. Biotechnol 
Bioeng 86, 765-774.
Huyghe, B.G., Liu, X., Sutjipto, S., Sugarman, B.J., Horn, M.T., Shepard, H.M., 
Scandella, C.J. and Shabram, P., 1995. Purification of a type 5 recombinant 
adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6, 
1403-16.
Iyer, P., Ostrove, J.M. and Vacante, D., 1999. Comparison of manufacturing 
techniques for adenovirus production. Cytotechnology 30, 169-172.
Jardon, M. and Garnier, A., 2003. pH, pCO2, and Temperature Effect on R-
Adenovirus Production. Biotechnol Prog 19, 202-208.
Kamen, A. and Henry, O., 2004. Development and optimization of an adenovirus 
production process. J Gene Med 6 Suppl 1, S184-192.
Matsudaira, P. 1990. Methods in enzymology. Press, A., editor. San Diego.
McQueen, A. and Bailey, J.E., 1991. Growth inhibition of hybridoma cells by 
ammonium ion: correlation with effects on intracellular pH. Biopr Eng 6, 49-61.
Mountain, A., 2000. Gene therapy: the first decade. Trends Biotechnol 18, 119-128.
Nadeau, I., Garnier, A., Côté, J., Massie, B., Chavarie, C. and Kamen, A., 1996. 
Improvement of recombinant protein production with human adenovirus/293S 
expression system using fed-batch Strategies. Biotechnol Bioeng 51, 613-623.
Nadeau, I., Gilbert, P.A., Jacob, D., Perrier, M. and Kamen, A., 2002. Low-protein 
medium affects the 293SF central metabolism during growth and infection with 
adenovirus. Biotechnol Bioeng 77, 91-104.
Nadeau, I., Jacob, D., Perrier, M. and Kamen, A., 2000a. 293SF Metabolic Flux  
analysis during cell growth and infection with an adenoviral vector. Biotechnol Prog 
16, 872-884.
Chapter III.1
80
Nadeau, I. and Kamen, A., 2003. Production of adenovirus vector for gene therapy. 
Biotechnol Adv 20, 475-489.
Nadeau, I., Sabatie, J., Koehl, M., Perrier, M. and Kamen, A., 2000b. Human 293 
cell metabolism in low glutamine-supplied culture: interpretation of metabolic 
changes through metabolic flux analysis. Metab Eng 2, 277-292.
Rea, D., Schagen, F.H., Hoeben, R.C., Mehtali, M., Havenga, M.J., Toes, R.E., 
Melief, C.J. and Offringa, R., 1999. Adenoviruses activate human dendritic cells 
without polarization toward a T-helper type 1-inducing subset. J Virol 73, 10245-
10253.
Xie, L., Pilbrough, W., Metallo, C., Zhong, T., Pikus, L., Leung, J., Aunins, J.G. 
and Zhou, W., 2002. Serum-free suspension cultivation of PER.C6R cells and 
recombinant adenovirus production under different pH conditions. Biotechnol 
Bioeng 80, 569-579.
                                    Ammonia effect on pHi and AdV production
81
PART 2
Effect of ammonia production on intracellular pH: consequent effect on 
adenovirus vector production
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Abstract
Recombinant adenoviral vectors (AdV) have proven to be highly efficient 
for the delivery and expression of foreign genes in a broad spectrum of cell 
types and species both for vaccination and gene therapy in a number of 
specific applications. 
In this study, the effect of ammonia production on intracellular pH (pHi) 
and consequently inhibition of AdV production at high cell densities is 
assessed. Different specific ammonia production rates were obtained for 
293 cells adapted to grow in glutamate supplemented medium (non-
ammoniagenic medium) as compared with 293 cells growing in glutamine 
supplemented medium (ammoniagenic medium); pHi was observed to be 
lower during cell growth and AdV production at both high and low CCI in 
the ammoniagenic medium, where the specific ammonia production rate is 
higher. In addition, after infection at CCI of 3106 cell/ml, the cell viability 
decreased significantly in the ammoniagenic medium, attributed to the 
activation of an acidic pathway of apoptosis. Furthermore, AdV DNA was 
observed to be degraded at the observed pHi in the ammoniagenic medium, 
decreasing significantly the amount of AdV DNA available for 
encapsidation. To elucidate the pHi effect upon AdV production, 293 cells 
were infected at a CCI of 1106 cell/ml in the non-ammoniagenic medium 
with a manipulated pHi as observed at the time of infection at CCI of 3106
cell/ml in the ammoniagenic (pHi 7.0) and non-ammoniagenic (pHi 7.3) 
media; AdV volumetric productivities were observed to be lower when the 
cells were exposed to the lower pHi. Thus, the importance of controlling all 
the factors contributing to pHi on AdV production, such as ammonia 
production, has been established.  
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1. INTRODUCTION
Recombinant adenoviral vectors (AdV) have proven to be highly efficient 
for the delivery and expression of foreign genes in a broad spectrum of cell 
types and species, in a number of specific applications (Volpers and 
Kochanek, 2004; Ferreira et al., 2005a). Thus, as the market needs for AdV 
are increasing, methodologies for production of concentrated AdV are 
needed. Although 293 cells can be grown up to 8106 cell/ml in batch 
systems (Ferreira et al., 2005c), AdV production at high cell densities is 
limited by the so-called “cell density effect”, i.e., a drop in cell specific 
productivity concomitant with increased cell concentration at infection 
(CCI) for values above 1106 cells/ml (Nadeau and Kamen, 2003; Kamen 
and Henry, 2004; Ferreira et al., 2005b). Although this effect has been 
attributed mainly to nutrient limitations and/or byproducts accumulation, 
the exact nature of the factors limiting AdV productivities at high CCIs 
remains unknown. Previous studies have indicated that medium 
replacement at the time of infection and the addition of glucose and amino 
acids at 24 h post infection (hpi) together with periodic pH adjustments, 
allows for high cell specific productivity at cell densities in the range 2106
to 3106 cells/ml (Garnier et al., 1994; Nadeau et al., 1996). Our group has 
shown that ammonia is an important parameter for infection at high cell 
densities, since, by adapting 293 cells to non-ammoniagenic medium, a 5 
fold increase on cell specific productivity could be obtained at a CCI of 
3×106 cell/ml (Ferreira et al., 2005b). However, the mechanisms by which 
ammonia inhibits AdV production remain unknown. 
Ammonia derives mainly from deamination of glutamine, whose 
concentration in the culture medium is usually 5 to 20 fold higher than that 
of other amino acids (Eagle, 1955). Complete catabolism of glutamine
produces 2 mol of ammonia per mol of glutamine. Other minor sources of 
ammonia include the spontaneous degradation of glutamine (Ozturk and 
Palsson, 1990; Arii et al., 1999) and catabolism of other amino acids.
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Several mechanisms of ammonia toxicity have been described in animal 
cells, including: disturbance of electrochemical gradients (Mirabet et al., 
1997); inhibition of enzyme reactions; changes in intracellular pH (pHi) 
(McQueen and Bailey, 1990); increased demand for energy maintenance 
(Martinelle and Haggstrom, 1993); inhibition of cell growth; and perturbed 
processing and secretion of proteins and apoptosis induction (Cruz et al., 
2000).
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Figure 3.2.1 Mechanisms influencing pHi at decreased medium pH, increased 
ammonium ion concentration, and increased medium osmolality (adapted from 
Cherlet and Marc (1998)).
In the case of pHi, ammonia can disturb the optimal cytoplasmatic pH by 
forming a “proton shuttle” (represented schematically in Figure 3.2.1):
briefly, the intracellularly originated ammonium ions (NH4
+) are rapidly 
excreted by passive diffusion, under the form of ammonia ions (NH3), to 
the extracellular milieu with concomitant accumulation inside the cell of 
one proton (H+) per NH3 molecule released. This excretion is facilitated by 
the negative charge of the membrane potential and the gradient of 
ammonia ions across the cell membrane. Once outside the cell, NH4
+ can 
enter the cell again propelled by the large electrical gradient due to the 
highly charged membrane and leave the cell again under the NH3 form; this
cycle can be started over and over again (McQueen and Bailey, 1990; Wu et 
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al., 1993). If this proton load is higher than the overall cell capacity to 
excrete it, the pHi decreases. If ammonium ions (NH4
+) are added to the 
culture medium, NH3 diffusion into cells predominates, leading to cell
alkalinization. In addition to ammonia, pHi can also be affected by 
extracellular pH (pHe) and osmolality (Wu et al., 1993) (Figure 3.2.1). 
However, these are not so critical for AdV production because pHe can be 
controlled in the bioreactors and high osmolality leads to cytoplasmic
alkalinization (Frelin et al., 1988).
It is known that AdVs have a low stability at acidic pH (Evans et al., 2004). 
Also, several studies describe the effect of pH on the stability of 
mammalian DNA namely on the correlation between pHi and the activity of 
the nuclear enzymes DNase I and DNase II (Barry and Eastman, 1993; 
Gottlieb et al., 1996; Matsuyama et al., 2000; Lagadic-Gossmann et al., 
2004). However, the mechanisms describing how pH affects AdV DNA are 
still unknown. 
In this work, we report on the effect of ammonia accumulation on pHi and 
its consequent effect on AdV production. For that purpose 293 cells 
adapted to grow in suspension in glutamine supplemented medium 
(ammoniagenic medium) and in glutamate supplemented medium (non-
ammoniagenic medium) were compared in terms of intracellular pH and 
AdV production.
2. MATERIALS AND METHODS
2.1. Cell line and medium
Anchorage-dependent 293 cells, purchased from ATCC (ATCC-CRL-1573), 
were cultured in Minimum Essential Medium (MEM) supplemented with 5% 
heat-inactivated (56 ºC, 30 min.) Foetal Bovine Serum (FBS) and 2 mM of 
glutamine (all from Invitrogen, Glasgow, UK) using a humidified 
atmosphere of 5% CO2 in air at 37ºC. The anchorage-dependent 293 cells 
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were further adapted to grow in suspension in commercially available 
serum and protein free medium, CD 293, supplemented with 4 mM of 
glutamine (ammoniagenic medium) (all from Invitrogen, Glasgow, UK) or 
glutamate (non-ammoniagenic medium) (Sigma-Aldrich, St. Louis, MO) in an
humidified atmosphere of 8% CO2 in air at 37ºC in shake flasks (Corning, 
NY). Cells were routinely propagated, twice a week, with an inoculum of 
0.5×106 cell/ml.
2.2. Infection in shake flasks
A replication-defective AdV derived from human Ad5 was kindly provided
by Dr. Tom Barret (Institute for Animal Health-Pirbright, UK). Infection was 
made in CD 293 medium when the cells reached a concentration (CCI) of 
1×106 cell/ml or 3×106 cell/ml using a multiplicity of infection (MOI) of 10
(see Annex A) in 125 ml shake flasks with a working volume of 40 ml in a 
humidified atmosphere of 8% CO2 in air at 37ºC. Infected 293 cells were 
harvested at 48 h post infection (hpi) (see Annex A), earlier determined as 
the optimal harvesting time (Ferreira et al., 2005b). In the studies where 
the pHi was changed, 293 cells were grown with non-ammoniagenic 
medium supplemented with 30 mM KCl and 20 l of 1 mM of the strong 
carboxylic ionophore nigericin (Pressman, 1976) (Invitrogen, Glasgow, UK) 
in absolute ethanol or 30 mM KCl and 20 l of absolute ethanol (control).
2.3. Virus culture samples preparation
Infected 293 cells were harvested at 48 hpi and centrifuged at 1000g for 10 
min. at 4ºC. The resulting cell supernatant was distributed into small 
aliquots and stored at -85ºC for extracellular virus titration. The resulting 
cell pellet was resuspended in a known volume of Tris buffer 10 mM, pH 8.0 
supplemented with 2 mM MgCl2 (Merck, Darmstadt, Germany) and 0.1% 
(v/v) Triton (Sigma-Aldrich, St. Louis, MO). Cells were disrupted by 
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vortexing for 1 min. and cell debris removed by centrifugation at 3000g for 
10 min. at 4ºC. The resulting cell lysate supernatant was dispensed into 
small aliquots and stored at -85ºC for quantification of intracellular viral 
content.
2.4. Adenoviral vector titration
AdV titration was done in Anchorage-dependent 293 cells seeded into 6 
well plates at 1106 cell/well. One day after, seeded cells were infected 
with 1 ml of serial dilutions of the AdV in MEM supplemented with 5% FBS. 
After 24 h of incubation the medium was removed and the cells covered 
with agarose mix: MEM 2 (Invitrogen, Glasgow, UK) supplemented with 1% 
(w/v) agarose (Sigma-Aldrich, St. Louis, MO), 5% (v/v) FBS and 15% (v/v) 
PBS. Plates were incubated in a humidified atmosphere of 5% CO2 in air at 
37ºC and observed at day 7 and day 14 for plaque forming units (pfu).
2.5. Intracellular pH measurement
pHi was monitored in viable cell suspensions of approx. 1106 cell/ml. 
Briefly, samples collected from the culture bulk, were centrifuged at 200g 
for 10 min. at 4ºC and the cell pellet resuspended in Earl’s balanced salt 
solution (EBSS) buffer pH 7.3 (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 
mM MgSO4, 5 mM glucose (all from Merck, Darmstadt, Germany) and 25 mM 
HEPES (Sigma-Aldrich, St. Louis, MO)) supplemented with 10 M of the well 
known cytosolic pH dye BCECF-AM (Invitrogen, Glasgow, UK); Data was 
acquired after incubation of the cell suspension for 45 min. at 37 ºC (to 
allow BCECF-AM to be hydrolysed by intracellular esterase into pH-
dependent fluorescent BCECF).
The calibration curve was done using labelled cells ressuspended in high 
[K+] buffer with pH of 6.0-8.0 in 0.2 pH units steps prepared by mixing 
appropriate proportions of 135 mM KH2PO4, 20 mM NaCl and 110 mM 
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K2HPO4, 20 mM NaCl (all from Merck, Darmstadt, Germany), containing 10 
M nigericin for 5 min. before flow cytometry. 
Data was acquired using a Flow cytometer CyFlow® Space (Partec, 
Germany) equipped with a blue solid state laser set at 488 nm. The green 
fluorescence (FLl) was selected using a 525 nm band pass filter, while the 
red fluorescence was obtained with a 610 nm long-pass filter (FL3). The 
ratio of the two signals was used in all experiments, directly calculated by 
the cytometer data analysis system. The ratio is given by the mean peak 
channel of the histogram ratio after analysis of 2.5104 cells. Data analysis 
was performed using FlowMax® software (Partec, Germany).
2.6. DNase II activity assay at different pH values
For the DNase II activity assay, 5 ml of a cell suspension (3106 cell/ml) in 
buffer containing 100 mM sodium acetate, 5 mM EDTA (Merck, Darmstadt, 
Germany) and 0.1% (v/v) Triton were disrupted by vortexing for 1 min. 
followed by centrifugation at 3000g for 10 min. at 4ºC. Afterwards, 250 l 
of AdV DNA was added to the supernatant; these were subsequently 
incubated at 37ºC during 1h at a pH range of 5.6-7.8 in 0.2 pH units. This 
AdV DNA was obtained by incubation of 2.5107 AdV (infectious particles) 
in 0.1% (v/v) SDS (Merck, Darmstadt, Germany) at 56 ºC for 10 min. 
2.7. Determination of adenovirus DNA by quantitative real time PCR
For the quantitative real time PCR a plasmid containing one copy of the 
gene of interest, was used as external standard for quantification; the size 
of the amplicon is 220 bp. DNA amplifications were done using the Light 
Cycler system with “Fast Start Master SYBR Green I kit” (Roche Diagnostics, 
Germany). For a 20 l PCR reaction, 2 l DNA template and 18 l of 
Mastermix were added to each capillary. The Mastermix was prepared to 
obtain a final concentration of 3 mM MgCl2 and 0.5 M of each primer in 
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each capillary. The oligonucleotide primers used were: forward primer (5’-
TCG TAG AAG TGG ACG GT-3’) and reverse primer (5’-GTG TTC GTG ACT 
GAA GC-3’). The primers were designed to blast only the gene of interest. 
AdV DNA was denatured for 10 min. at 95ºC. The standard amplification 
program included 30 three-step cycles: (i) denaturation–heating at 95ºC for 
1 s, (ii) annealing–cooling at 56ºC during 5 s, and (iii) elongation–heating at 
72ºC for 10 s. Fluorescence was acquired at the end of the elongation step 
of each cycle. Data were analysed using the Light Cycler software and the 
“fit points method” described elsewhere (Rasmussen et al., 1998).
2.8. Analytical Methods
Cell concentration was determined by counting cells on a Fuchs-Rosenthal 
haemocytometer (Brand, Wertheim, Germany). Cell viability was 
determined by incubation of 293 cells with 1 g/ml propidium iodide (PI) 
(Invitrogen, Glasgow, UK). The cell suspensions were analysed in the flow 
cytometer - CyFlow® Space (Partec, Germany).
Ammonia was quantified enzymatically using a UV test number 1112732035 
(Boehringer Mannheim, R-Biopharm AG, Germany).
3. RESULTS AND DISCUSSION
3.1. Effect of ammonia addition on adenovirus vector production
To evaluate the effect of extracellular ammonia on cell specific 
productivity, NH4Cl was added to the culture medium at the time of 
infection at CCI of 1106 cell/ml. The viruses were harvested at 48 hpi and 
titrated. The results obtained show that, for all the tested concentrations 
(1.0, 1.5, 2.0, 2.5, 3.0 and 3.5 mM NH4
+), there is no significant effect on 
AdV production (Figure 3.2.2). 
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Figure 3.2.2. Effect of added ammonia on cell specific productivity. Cells were 
infected at a CCI of 1106 cell/ml with a MOI of 10 in non ammoniagenic medium 
after addition of NH4Cl and harvested at 48 hpi.
An inhibitory effect of extracellular ammonia on AdV production for 
concentrations above 1.5 mM has been reported (Ferreira et al., 2005b), 
this causing major problems for AdV production at high cell densities. 
However these studies were done without external addition of NH4
+ to the 
culture medium, the inhibitory effect becoming a direct consequence of 
the accumulation of ammonia derived mainly from cell metabolism, i.e. 
deamination of glutamine. The results reported herein (figure 3.2.2) 
suggest that ammonia has a different role when derived from an 
intracellular origin. Thus, an experimental approach allowing to study the 
effect of increasing concentrations of produced ammonia will mimic more 
faithfully the environment that the cells face in the bioreactor during AdV 
production. This can be achieved using non-ammoniagenic media.
3.2. Effect of ammonia on intracellular pH during cell growth
To evaluate the effect of produced ammonia on pHi during cell growth, 293 
cells adapted to grow in non-ammoniagenic medium (qammonia = 0.0910-9
mmol/cell.h) were compared with 293 cells growing in ammoniagenic 
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medium (qammonia = 410-9 mmol/cell.h) in terms of growth, ammonia 
production and pHi. As shown in Figure 3.2.3, for the non-ammoniagenic 
medium, the cells were able to maintain the pHi between 7.2 and 7.3 
throughout all the culture; for ammoniagenic medium the pHi was 
considerably lower: a drop of 0.2 units was evident at time 0 h and, as cells
reached the concentration of 2106 cell/ml (at 96 h), a significant decrease 
in pHi was registered.
For the non-ammoniagenic medium, the pHe was maintained at 7.20 during 
all the culture time. For the ammoniagenic medium, a decrease of 0.05 
(from 7.20 to 7.15) was observed from time 0 to time 96; however, this 
decrease was not as significant as the one observed for the pHi.
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Figure 3.2.3. Evaluation of pHi (empty symbols) during 293 cells growth (full 
symbols) in ammoniagenic medium (circles) and non-ammoniagenic medium 
(triangles).
By monitoring ammonia concentration it is possible to correlate the 
changes observed in pHi with the ammonia production (Figure 3.2.4). As 
expected, for the non-amoniagenic medium the production of ammonia 
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was significantly lower than for the ammoniagenic medium. The observed 
delay in pHi decrease relative to the faster enhancement of ammonia 
concentration in the culture medium can be related with the increasing 
number of “proton shuttle” cycles (McQueen and Bailey, 1990; Wu et al., 
1993) leading to a much higher uptake of protons then the overall cell 
capacity to excrete them.
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Figure 3.2.4. Relationship between pHi (empty symbols) and ammonia production 
(full symbols) in ammoniagenic medium (circles) and non-ammoniagenic medium 
(triangles).
3.3. Evaluation of ammonia production and intracellular pH during 
adenovirus vector production at different CCIs
In order to evaluate the effect of produced ammonia on pHi during the 
production of AdV at a CCI of 1 and 3×106 cell/ml, 293 cells were infected 
in either non-ammoniagenic and ammoniagenic media. As can be observed 
in Figure 3.2.5, the pHi is severely affected after infection, independently 
of the medium and CCI used. However, for both culture media tested, this 
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decrease is more pronounced when the infection is performed at CCI of 
3×106 cell/ml, especially for ammoniagenic media.
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Figure 3.2.5. Evaluation of pHi (empty symbols) and ammonia (full symbols) during 
AdV productions at CCI of 1106 cell/ml in ammoniagenic medium (squares) and 
non-ammoniagenic medium (diamonds) and CCI of 3106 cell/ml in ammoniagenic 
medium (circles) and non-ammoniagenic medium (triangles) with a MOI of 10.
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The specific ammonia production rate was not significantly affected when 
the CCI increased from 1 to 3×106 cell/ml, thus the observed pHi decrease 
(Figure 3.2.5) seems to be promoted by other factors than the ammonia 
production. Matsuyama et al. (2000) shown that a very early event in 
apoptosis involves a change on the pHi regulation, meaning that the 
significant decrease observed in pHi after AdV infection may be a way to 
the cell respond to infection by entering in apoptosis. In addition, 
Matsuyama et al. (2000) have shown that the efficiency of caspase 
activation, responsible for the beginning of the apoptosis process, is pH 
sensitive, with an in vitro pH optimum of approximately 6.6. In fact, the 
amount of viable cells after infection at CCI of 3106 cell/ml start to 
undergo a more pronounced decrease when the pHi reaches the value of 
6.6 (Figure 3.2.5) at 24 hpi for the ammoniagenic medium versus 36 hpi for 
the non-ammoniagenic medium (Figure 3.2.6); this means that cells are 
kept viable after infection for a longer time when the non-ammoniagenic 
medium is used.
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Figure 3.2.6. Effect of CCI of 3106 cell/ml in cell viability (full symbols) and 
percentage of dead cells (empty symbols) in ammoniagenic medium (circles) and 
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non-ammoniagenic medium (triangles).
3.4. DNase II effect upon adenovirus vector DNA at different pHs
To evaluate how pHi affects DNase II activity and consequently AdV DNA, 
incubations of the viral DNA were done at different pH values. As shown in 
Figure 3.2.7, pH affects the activity of DNase II upon the AdV DNA, a 
significant decline being observed for pH values below 6.6. No significant 
effects in AdV DNA were observed for similar studies performed with DNase 
I (data not shown). 
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Figure 3.2.7. Effect of pH on the activity of DNase II. AdV DNA was incubated with 
a cell supernatant extract as described in material and methods. () Represents 
the initial amount of AdV DNA observed at time 0 for each pH tested.  
Comparing the activity of DNase II with the pHi profiles after infection at a 
CCI of 1 and 3106 cell/ml in the ammoniagenic and non-ammoniagenic 
medium (Figure 3.2.5), it is possible to conclude that at CCI of 1106
cell/ml, independently of the medium used, only at the end of the 
production process the pHi reach values below 6.6. On the other hand, 
when cells are infected at CCI of 3106 cell/ml in the ammoniagenic 
medium, the pHi reach the 6.6 units faster than in the non-ammoniagenic 
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medium. Thus, for ammoniagenic media, due to the significant increase on 
DNase II activity for values below pH 6.6, more AdV DNA degradation will 
occur leading to less availability of virus DNA for encapsidation with a 
consequent decrease in bioactive AdV production.
3.5. Effect of intracellular pH on adenovirus vector production
To elucidate the pHi effect upon AdV production, 293 cells adapted to grow 
in the non-ammoniagenic medium were infected at a CCI of 1106 cell/ml 
at pH 7.0 or at pH 7.3 (pHi observed at the time of infection at CCI of 3106
cell/ml in the ammoniagenic and non-ammoniagenic media respectively), 
with or without nigericin addition and harvested at 48 hpi. Nigericin was 
used to mimic the pHi observed at CCI 3106 cell/ml in both media at pHi
7.0 and 7.3.
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Figure 3.2.8. Effect of pHi on AdV volumetric productivity. pHi was decreased by 
addition of 30 mM KCl and of 50 M nigericin as described in material and methods.  
As can be observed in Figure 3.2.8, although there is no significant 
difference on AdV production at pH 7.0 or at pH 7.3 in control conditions, 
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when nigericin is used a drop in AdV volumetric productivity is observed for 
both pHs, although it is more pronounced at pH 7.0. Despite the fact that 
nigericin has a residual cytotoxic effect (data not shown), it is obvious 
that, for a pH of 7.0, AdV volumetric productivity is strongly affected. 
These results reflect the impact of the pHi on AdV production and the 
overall need to minimize all the factors that contribute to its decrease, 
such as the intracellular ammonia production.
4. CONCLUSIONS
The present study compares the effect of two different culture media 
leading to different specific ammonia production rates, upon pHi and AdV 
productivity in 293 cells infected at different CCIs (1 and 3×106 cell/ml). 
During cell growth the pHi decreased significantly in the ammoniagenic 
medium, where the specific ammonia production rate is higher; 
furthermore, after infection, the pHi dropped significantly at both CCIs for 
both media, although the lowest pHi was obtained for the ammoniagenic 
medium. These changes observed in the pHi were found to play an 
important role on both processes of apoptosis and AdV DNA degradation, 
leading to a decrease in bioactive AdV production, more severe for the 
ammoniagenic medium.
The data reported herein identifies pHi as one of the key factors 
responsible for the “cell density effect” observed on AdV production. Non-
ammoniagenic medium was shown as a good option to be implemented at 
the bioreaction level that will lead to the maintenance of cell viability 
during AdV production and consequent increase on cell specific 
productivity.
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PART 1
The importance of 293 cell cycle phase on adenovirus vector production
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Abstract
One of the major restrictions on the production of adenoviral vectors (AdV) 
is the so-called “cell density effect”, i.e., a drop in cell specific 
productivity concomitant with increased cell concentration at infection 
(CCI) above 1106 cell/ml. Although this “cell density effect” has been
considered by several authors as a consequence of nutrient depletion 
and/or accumulation of byproducts, this study shows that the cell fraction 
at the S phase of the cell cycle may also play a role on AdV production at 
high CCI in 293 batch cultures. By infecting cells obtained from different 
growth stages at cell densities of 0.7 (lag), 1.6 (middle exponential), 3.3 
(late exponential) and 5.0106 (stationary) cell/ml, consisting of a 
descending proportion of cells in the S phase in the cell cycle in equalized 
cell density condition, it is shown that cell specific productivity is 
dependent on the cell cycle phase at infection at both the optimal CCI 
(1106 cell/ml) and high CCI (4106 cell/ml). In particular, under the 
equalized cell density conditions, the infection of cells with an S phase 
proportion of 50% at the high CCI gave the higher AdV volumetric 
productivity. Moreover, the lowest cell specific productivity was obtained 
with the lowest S phase proportion of 28% for both CCIs. These results 
indicate that a decrease in the proportion of cells at S phase at the time of 
infection also contributes to a decreased cell specific productivity at high 
cell densities.
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1. INTRODUCTION
AdV have been extensively used as vectors for both gene therapy and 
recombinant DNA vaccines, which have been tested in both humans and 
different animal species (Ferreira et al., 2005a). The need for large 
quantities of clinical-grade AdV is an important limitation to in vitro 
experimentations as well as to pre-clinical and clinical studies (Nadeau and 
Kamen 2003; Kamen and Henry 2004). This limitation is due to the fact 
that the cell specific productivity decreases sharply with increased CCI 
above 1106 cell/ml, the so called “cell density effect”. So far, this “cell 
density effect” has been attributed to nutrient limitations and/or 
accumulation of byproducts (Nadeau and Kamen 2003; Henry et al., 2004; 
Kamen and Henry 2004; Ferreira et al., 2005b). Although metabolic flux 
analysis has been used to characterize the effect of various environmental 
conditions upon cell metabolism, the exact nature of the factors limiting 
AdV productivities at high cell density remains unknown (Nadeau et al., 
2000a; Nadeau et al., 2000b; Nadeau et al., 2002). Therefore, present 
strategies for overcoming this bottleneck have been focused on the 
improvement of cell growth environment during and after infection. These 
strategies include medium replacement at the time of infection and the 
addition of glucose at 24 hour post infection (hpi) together with periodical 
pH adjustments, allowing a sustained maximum specific productivity at 
1.6106 cell/ml (Garnier et al., 1994). This strategy, associated with 
essential amino acids feeding at 24 hpi, is able to stabilise the volumetric 
productivity at cell densities up to 2106 cell/ml (Nadeau et al., 1996).
Perfusion mode operation has been demonstrated as the most effective 
measure to control the culture environment and to remove toxic 
byproducts (Cortin et al., 2004; Henry et al., 2004; Kamen and Henry 
2004). Nevertheless, the cell specific productivity could only be maintained 
by infecting cells at densities up to 3106 cell/ml using high perfusion rate 
at 2 reactor volumes per day (VVD), at 2 days post-infection, a very costly 
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proposition (Henry et al., 2004; Kamen and Henry 2004). By decreasing the 
temperature to 35 oC post infection, Cortin et al. (2004) have further 
increased CCI up to 8106 cell/ml at perfusion rate of 1 VVD with a 
production of 7.8109 infectious particles/ml (ip/ml). In studies conducted 
by the authors under much less expensive fed batch mode using 293 cells 
adapted to non-ammoniagenic medium an 1.8 fold increase on AdV 
volumetric productivity at CCI 3106 cell/ml was obtained, when comparing 
with infection at CCI 1106 cell/ml in the same medium, with a production 
of 8.5109 ip/ml (Ferreira et al., 2005b; Ferreira et al., 2005c).
During cell culture processes, especially in batch and fed-batch mode, 
apart from the continuously changing culture chemical and physical 
environment, the cells themselves are also continuously varying their 
physiological and metabolic states. It is well known that during the 
culturing, the population of cells goes through four growth stages, i.e., lag, 
exponential, stationary and death-phase, where an individual cell commits 
to four successive growth phases in the cell cycle, i.e., G1 (gap one phase, 
between mitosis and DNA synthesis), S (DNA synthesis phase), G2 (gap two 
phase, between completion of DNA synthesis and mitosis) and M-phase 
(mitosis phase). In some cases, cells may escape from the cell cycle and 
enter a resting phase (G0), from where, given suitable condition, they can 
return to the cell cycle. During the culture process, the cell cycle phase 
distribution may be continuously changing and no matter in which phase of 
the cell cycle the cells are infected by AdV, the viral DNA synthesis will 
only take place 9h after infection (Hodge and Scharff 1969).
The effect of cell cycle phase at the time of infection on AdV productivity 
has not been well described. The scarce reported data suggests that it is 
both cell line and virus type dependent. For avian AdV, both production of 
infectious virus and viral DNA synthesis are correlated with events during 
the S phase of the infected chicken embryo fibroblasts cells (Kraft and 
Tischer 1978). For HeLa cells, infection with human Ad5 during S phase 
produced greater yields of E1B 55-kDa-mutant and E4 orf6-mutant viruses 
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than did cells infected during G1 or asynchronous cells. However the 
production of wild Ad and E4 orf3-mutant Ad was not significantly 
restricted by the cell cycle (Goodrum and Ornelles 1997). In addition, for 
many other viruses, the production is associated with the S phase of the 
cell cycle. For example, coxsackievirus production is dependent on G1 or 
G1/S phase (Feuer et al., 2002); for minute virus of mice, a parvovirus, the 
conversion of the viral genome from input single-stranded DNA to a double-
stranded DNA, the form which undergoes further replication, appears to be 
an S phase-specific event (Wolter et al., 1980); in the baculovirus-insect 
cell expression system, the infection yield at G1 or S phase-infection was 
1.5-1.8-fold higher than that at G2/M phase-infection (Saito et al., 2002);
the replication of the bovine herpesvirus-4 depends on transition through S 
phase (Vanderplasschen et al., 1995); the herpes simplex virus type 1 
vmw65 (VP16) insertion mutant depends on cells infected during S phase 
for early protein synthesis and replication (Daksis and Preston 1992).
Thus the aim of this work is to investigate the importance of the cell cycle 
phase of the host 293 cells at the time of infection upon AdV productivity, 
so that more efficient infections at high cell density may be achieved.
2. MATERIALS AND METHODS
2.1. Cell line and culture maintenance
Suspension-adapted 293 cells (ATCC-CRL-1573, Rockville, MD) were grown 
in shake flasks (Corning, NY) in commercially available and chemically 
defined medium without serum and protein, CD293, supplemented with 4 
mM of L-glutamine (all from, Invitrogen, Glasgow, UK) at 160 rpm under an 
humidified atmosphere of 8% CO2 in air at 37ºC. The cells were routinely 
propagated twice a week with an inoculum density of 0.5106 cell/ml.
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2.2. Cell infection
A replication-defective AdV derived from type 5 AdV was kindly provided by 
Dr. Tom Barret (IAH-Pirbright, UK). Infection was carried out in 125 ml 
shake flasks with working volumes of 40 ml using a multiplicity of infection 
(MOI) of 10 (see Annex A). Infected 293 cells were harvested at 0, 24, 48 
and 72 hpi and prepared as previously described in Ferreira et al. (2005b)
2.3. Analytical methods
Cell concentration and viability were determined by counting cells on a 
Fuchs-Rosenthal haemocytometer (Brand, Wertheim, Germany) using the 
trypan blue (Invitrogen, Glasgow, UK) dye exclusion method.
AdV titration was performed by the end-point dilution method (TCID50) 
using 96 well plates and anchorage-dependent 293 cells cultured in T-flasks 
(Sarstedt); these cells were cultured in MEM supplemented with heat-
inactivated 5% fetal bovine serum (all from Invitrogen, Glasgow, UK) and 2 
mM L-glutamine under an humidified atmosphere of 5% CO2 in air at 37 
oC. 
The titer was determined according to the method of Spearman and 
Kraber, as described elsewhere (Darling et al., 1998).
Glucose and lactate were analyzed using an YSI Multiparameter 
Bioanalytical System Model 7100 MBS (Yellow Springs, USA).
Ammonia was quantified enzymatically using the UV test number 
1112732035 (Roche Diagnostics GmbH, Mannheim, Germany).
2.4. Flow cytometric analysis
To quantify the cell-cycle distribution, cells were stained with propidium 
iodide to measure the DNA content by flow-cytometric analysis (FACS). 
Cells were centrifuged at 200 g for 10 min at 4ºC, washed with ice-cold PBS 
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and stained with ice-cold Vindelov’s solution (Vindelov et al., 1983): 1 g/l 
trisodic citrate, pH 7.6 (Sigma); 50 mg/l propidium iodide (Sigma); 0.1% NP 
40 (Roche); 700 U/l RNase A (Sigma); 0.01 M NaCl (Merck) for a final cell 
concentration of 1.5106 cell/ml. All FACS analyses were performed on a 
FACSCaliburTM using the Cell QuestTM software (Beckton-Dickinson, San 
Jose, CA).
3. RESULTS AND DISCUSSION
3.1. Relationship between cell density and cell cycle phase 
distribution during normal batch cultures of 293 cells
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6
Time after inoculation (days)
V
ia
b
le
 c
el
l d
en
si
ty
0
10
20
30
40
50
60
70
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
V
ia
b
le
 c
el
l d
en
si
ty
V
ia
b
le
 c
el
l d
en
si
ty
(1
06
ce
ll
/m
l)
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
V
ia
b
le
 c
el
l d
en
si
ty
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
V
ia
b
le
 c
el
l d
en
si
ty
V
ia
b
le
 c
el
l d
en
si
ty
(1
06
ce
ll
/m
l)
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
P
h
as
e 
in
 t
h
e 
ce
ll
 c
yc
le
 
(p
er
ce
n
ta
ge
 o
f 
p
op
u
la
ti
on
)
Figure 4.1.1.  Profiles of cell growth and cell cycle phase distribution during 293 
cell suspension batch cultures. Symbols: , cell density; , G2/M phase; , G1/G0 
phase; ▲, S phase.
Figure 4.1.1 describes the cell cycle phase distribution at different cell 
densities during a normal batch cultivation process of 293 cells. After 
inoculation, the proportion of cells in the S phase of the cell cycle 
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increased sharply, with a 70% increase within the first 24 h, from ca. 30% 
to ca. 50% of the total cell population. Conversely, the percentage of 
G1/G0 cells in the cell culture fell during this period. The highest S phase 
proportion occurred at the middle of the lag phase of the growth stage, 
corresponding to a cell density of 0.6-0.8106 cell/ml. Thereafter, the 
percentage of cells in the S phase decreased gradually, as the cell density 
increased above 1106 cell/ml; correspondingly, the percentage of G1/G0 
cells in the cell culture rose, while the percentage of cells at G2/M phase 
was kept relatively stable at about 11% during the whole growth cycle. 
Accompanying the cell density increase, the nutrients in the culture 
medium, namely glucose and glutamine, decreased quickly; at the same 
time, the accumulation of the byproducts, specially lactate and ammonia,
increased rapidly in the 293 cell suspension batch cultures (Figure 4.1.2).
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Figure 4.1.2.  Kinetics of total glucose (Glc, ) and glutamine (Gln, ) 
consumption and total lactate (Lac, ) and ammonia (NH4+, ∆) production of 293 
cell suspension batch cultures.
Although Lullau et al. (2003) observed for 293-BACE-Fc a higher S phase 
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fraction at the end of batch culture, the trend in the cell cycle phase 
distribution of 293 cells obtained here is well supported by others who 
observed similar results for cultures of hybridoma cells (Ramirez and 
Mutharasan 1992; Balcarcel and Stephanopoulos 2001; Luo and Yang 2004),
CHO cells (Ley and Tobey 1970; Tobey and Ley 1970) and Hela cells (Koza 
and Herbst 1992; Goodrum and Ornelles 1997).
3.2. Effect of different proportion of cells under S phase in equalized 
cell density conditions upon AdV productivity
As demonstrated above, the proportion of cells in the S phase decreased as 
the cell density rose. To evaluate if this decreased proportion of cells in 
the S phase at high cell density correlates with the so called “cell density 
effect”, cells were infected at different growth stages with different 
proportions at S phase under equalized cell density conditions at CCI of 
1106 cell/ml. In brief, after harvesting, the cells were centrifuged to 
totally remove the spent medium, and then resuspended in fresh medium 
at a final concentration of 1106 cell/ml before infection, and infected 
with the same MOI at the same time. As stated in the Introduction, the CCI 
of 1106 cell/ml was chosen on the basis of the observations that it is the 
optimum CCI for normal AdV production (Ferreira et al., 2005c). The 
medium exchange was performed to avoid lack of nutrients and presence 
of toxic byproduct thus permitting to isolate the evaluation of the cell 
cycle effect. The results are illustrated in Figure 4.1.3 and summarized in 
Table 4.1.1. 
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Figure 4.1.3.  Profiles of cell specific productivity of cells obtained from different 
growth stages with different proportions in S phase at the time of infection in 
equalized cell density conditions at a CCI of 1106 cell/ml. The 293 cells for this 
experiment were harvested from lag, middle exponential, late exponential and 
stationary phases, corresponding to cell densities of 0.7, 1.6, 3.3, and 5106
cell/ml, with proportions of cells in S phase of 50% (▲), 40% (), 32% () and 28% 
(Δ), respectively. The cells were centrifuged to discard the spent medium and 
replaced with fresh medium at CCI of 1106 cell/ml, in order to provide an 
equalized infection environmental condition for all the cells. 
Table 4.1.1. Effect of cells obtained from different growth stages with different 
proportions in S phase at the time of infection in cell specific productivity at 
the optimal cell concentration at infection (1106 cell/ml). Infections were 
performed at MOI of 10 and AdV harvested at 72 hpi.
Growth stage 
of cells
Original cell 
density (cell/ml)
Percentage of S phase 
cells at infection
Maximum cell specific 
productivity (ip/cell)
Lag 0.7106 50%  3% 8.3103  0.7103
Middle 
exponential
1.6106 40%  3% 4.7103  0.4103
Later 
exponential
3.3106 32%  2% 2.5103  0.3103
Stationary 5.0 28%  2% 1.3103  0.5103
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The infection of cells from the lag phase, with the highest proportion at S 
phase, resulted in the highest productivity of 8.3103 ip/cell at 72 hpi, 6.4
times higher than the level of cells obtained from stationary phase with the 
lowest proportion in S phase at the same time (1.3103 ip/cell). In other 
words, even though all infections were performed at the optimal CCI (1106
cell/ml), cells obtained from different growth stages exhibited different 
cell specific productivities. These results strongly support the hypothesis 
that the cell specific productivity is dependent upon cell cycle at infection, 
i.e., higher proportion of cells at S phase, corresponding to a larger cell 
population under faster division, resulted in higher AdV productivities.
Interestingly, cells obtained from the growth stages at higher cell densities 
of 3.3 and 5.0106 cell/ml presented a lower cell specific production rate 
and a higher optimal harvesting time of 72 hpi although 48 hpi is the 
optimal harvesting time for the cells obtained from the growth stages at 
lower cell densities of 0.7 and 1.6106 cell/ml (Figure 4.1.3). Although this 
effect could be correlated with cell aggregation in the experiments 
performed at high cell densities, no significant cell aggregation (no more 
than 2-4 cells aggregates) was found. Moreover, an increase of 60% on 
viable cell density at 24 hpi for cells with the higher proportion in S phase 
was observed (Figure 4.1.4). Hodge and Scharff (1969) observed that no 
matter in which phase of the cell cycle the cells are infected, the viral DNA 
will start to be produced at 9 hpi, meaning that a cell in G1 phase will stop 
at the S phase and that a cell in the S phase will double once more after 
infection; therefore it is not surprising to observe cell growth after 
infection where the proportion of cells on the S phase of the cell cycle is 
higher.
                                                                         Importance of cell cycle
117
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
0 24 48 72
Time post infection (hours)
V
ia
b
le
 c
el
l d
en
si
ty
 (
10
6
ce
ll
/m
l)
V
ia
b
le
 c
el
l d
en
si
ty
 (
10
6
ce
ll
/m
l)
V
ia
b
le
 c
el
l d
en
si
ty
 (
10
6
ce
ll
/m
l)
V
ia
b
le
 c
el
l d
en
si
ty
 (
10
6
ce
ll
/m
l)
Figure 4.1.4.  Profiles of cell growth after infection in equalized cell density 
conditions at a CCI of 1106 cell/ml. The 293 cells for this experiment were 
harvested from lag, middle exponential, late exponential and stationary phases, 
corresponding to cell densities of 0.7, 1.6, 3.3, and 5106 cell/ml, with proportions 
of cells in S phase of 50% (▲), 40% (), 32% () and 28% (Δ), respectively.
The effect of different proportion of cells under S phase at infection on 
AdV productivity was further investigated at higher CCI in the equalized 
cell density conditions. In this case, the CCI of 4106 cell/ml was chosen in 
order to highlight the difference in cell specific productivity in the 
equalized cell density condition. As illustrated in Figure 4.1.5, similarly to 
the results achieved at the optimal CCI of 1106 cell/ml, at the CCI of 
4106 cell/ml the infection of cell cultures with higher proportion in S 
phase also resulted in higher cell specific productivity. At this CCI, the 
infection of cells with the highest S phase proportion (50%), resulted in a 
production of 2.5103 ip/cell at 72 hpi. This cell specific productivity was 
16.7-fold higher than that obtained from infection of cells from the 
stationary growth stage at a cell density of 5106 cell/ml, consisting of the 
lowest S phase cell proportion (28%), and resulted in the higher volumetric 
productivity of 11010 ip/ml (Figure 4.1.5). Once more, this constitute 
strong evidence that the proportion of cells in S phase at infection is an 
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important parameter affecting cell specific productivity at both the 
optimum and even at higher CCIs. However, for the same cell population, 
infections at CCI of 1106 cell/ml always resulted in a significantly higher 
cell specific productivity than infections at CCI of 4106 cell/ml; this may 
be due to the higher accumulation of ammonia and lactate at CCI of 4106
cell/ml (data not shown), excess of ammonia being inhibitory of AdV 
production (Ferreira et al., 2005b). In fact, concomitantly with lower cell
specific productivity, the cell viability after infection dropped faster at CCI 
of 4106 cell/ml than it did at CCI of 1106 cell/ml (data not shown).
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Figure 4.1.5.  Comparison of maximal cell specific productivity obtained after 
infection at the optimal CCI of 1106 cell/ml () and at the high CCI of 4106
cell/ml () against proportion of cells in S phase at infection. The 293 cells for this 
experiment were harvested from lag, middle exponential, late exponential and 
stable phases, respectively, consisting of different proportion of cells in S phase 
(see text). Infections were performed at an MOI 10 and AdV harvested at 72 hpi.
As shown in this work, the AdV productivity is dependent upon the cell 
cycle phase at infection. Thus, cell specific productivity may be improved, 
especially at high CCI, by synchronizing 293 cells and infecting the cells at 
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higher proportions of cells in the S phase. However, the mechanism 
involved in this process is still unclear. It may be possible that the 
transcription and translation level of the E1 gene in the S phase of the 293 
cells is higher than in G1/G0 phase. In addition, the larger volume of the 
cells in S phase than in G1/G0 phase may also be responsible for the higher 
cell specific productivity.
4. CONCLUSION
This study shows that the proportion of cells at the S phase in the cell cycle 
decreased gradually at cell densities above 1106 cell/ml in 293 batch 
cultures. In addition, infections of cells from “naturally grown” populations 
at different densities with different proportions of cells in S phase in 
equalized cell density conditions demonstrate that cell specific 
productivity is cell cycle phase dependent at the time of infection. In 
particular, infection of cells obtained from lag growth phase, having the 
highest proportion of cells in S phase (50%) in the equalized condition, 
resulted in the higher AdV volumetric productivity of 11010 ip/ml at a CCI 
of 4106 cell/ml. These results indicate that the increase in the proportion 
of cells at the S phase in the cell population represents an increase on cell
specific productivity at high cell densities. In addition, these results show 
also that the inoculum play a significant role, not only in the maximal cell 
density and specific growth rate [30], but also in cell specific productivity, 
being an important parameter to consider on AdV production.
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293 cell cycle synchronisation in adenovirus production
Ferreira T.B., Perdigão R., Carina A.C., Zhang C., Aunins J.G., Carrondo 
M.J.T., Alves P.M. Biotechnol. Bioeng. (submitted)
Chapter IV.2
126
Abstract
As the market requirements for adenovirus vectors (AdV) increase, the 
maximisation of the virus productivity per culture volume per unit time is a
key requirement. However, despite the fact that 293 cells can grow up to 
8×106 cell/ml in simple batch mode operations, for optimal AdV infection a 
maximum cell density of 1×106 cell/ml at infection time has been reported. 
In addition, AdV production appears to be dependent of the cell cycle 
phase at the time of infection. To evaluate the dependence of AdV 
production on cell cycle phase, 293 cells were chemically synchronised at 
each phase of the cell cycle; a 2.6 fold increase on cell specific 
productivity was obtained when the percentage of cells at the S phase of 
the cell cycle was increased from 36% to 47%. A mathematical equation 
was used to relate AdV productivities with S phase cell synchronisation 
using this data.
A temperature shift strategy was also used attempted for synchronisation
at the S phase, avoiding the use of chemical inhibitors. S phase 
synchronisation was possible by decreasing the culture temperature to 31ºC 
during 67h and restoring it to 37ºC during 72h. By using this strategy we 
were able to synchronise 57% of the population in the S phase of the cell 
cycle obtaining an increase of 7.3 fold on cell specific productivity after
infection.  
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1. INTRODUCTION
Adenoviruses are leading vectors for gene transfer, with products in 
development for applications ranging from cancer therapeutics to 
prophylactic vaccines and replacement therapies for genetic deficiencies
(for reviews see Gallo et al. (2005), Ferreira et al. (2005a) and Morsy et 
al., (1998)); worldwide, over 300 clinical trials using Adenovirus Vectors 
(AdV) have already been approved, ongoing or completed, making AdV the 
most used delivery vector in clinical trials (www.wiley.co.uk/genetherapy/
clinical).
One of the goals of a commercial AdV cultivation process is to maximize 
the virus productivity per culture volume per unit time. The cell density at 
infection is a very important parameter as it impacts on the AdV 
volumetric productivity. However, despite the fact that 293 cells can grow 
up to 8×106 cell/ml in simple batch mode operations, a maximum infection 
cell density of 1×106 cell/ml has been reported as optimal (Nadeau and 
Kamen, 2003; Xie et al., 2003; Kamen and Henry, 2004; Ferreira et al., 
2005c; Maranga et al., 2005). An approach to maintain cell specific 
productivity at increased cell density consists of infecting the cells after 
medium exchange (Garnier et al., 1994; Iyer et al., 1999; Ferreira et al., 
2005b). However, this procedure adds the extra complexity of a cell 
separation step and increases in product production cost due to medium 
exchange. Other approach consists in the use of a fed-batch strategy, but 
its success has been limited (Nadeau et al., 1996; Ferreira et al., 2005b). 
By using a non-ammoniagenic medium an increase of 5 fold on cell specific 
productivity could be obtained at a CCI of 3×106 cell/ml still bellow the 
expected (Ferreira et al., 2005b). 
AdV production is usually performed assuming that cultured cells represent 
a uniform target for the virus. However, in fact, cells in culture are not 
homogenous, including a collection of cells with distinct physiologies. A 
major determinant of cell physiology in culture is the cell cycle with its 
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four stages (Stein et al., 1999) including elevated protein synthesis (G1 and 
G2 phases), elevated DNA synthesis (S phase) and changes in membrane 
trafficking, cytoskeletal organization and cell-cell interactions (M phase). 
In Chapter IV, Part 1 was shown that AdV production seems to be 
dependent of the cell cycle phase at the time of infection: during cell 
growth the highest percentage of cells at the S phase of the cell cycle is 
present at approximately 1×106 cell/ml, which has been shown to be the 
optimal concentration for AdV infection, decreasing with increasing cell 
density (Zhang et al., 2006). Furthermore, Goodrum and Ornelles (1997)
observed that in synchronously growing HeLa cells, approximately 75% of 
the cells infected during S phase, produced E1B AdV mutant virus, whereas 
only 10% of the cells infected during G1 phase were able to produce virus. 
Therefore, it is pertinent to synchronize cells at each phase of the cell 
cycle in order to identify the best phase for infection to increase cell 
specific productivity at high cell densities. Several methods for obtaining 
synchronised populations of mammalian cells in vitro have been reported 
by using genetic, chemical, environmental and physical strategies (Davis et 
al., 2001). For reversible chemical synchronisation several compounds are 
available, as thymidine (Law et al., 2006) for G1 phase synchronisation, 
mimosine (Hughes and Cook, 1996) for late G1 phase synchronisation, 
aphidicolin (Jackson, 1995), rapamicine (Law et al., 2006) and hydroxyurea 
(Rosenkranz and Becker, 1973) for synchronisation at the G1/S transition 
phase, staurosporine (Kocher and Clemetson, 1991) for G2 phase 
synchronisation and nocodazole (Ho et al., 2001) for synchronisation at the 
G2/M transition phase. However, in addition to the difficulty in ensuring
their elimination in the final product, the use of these chemicals as 
synchronising agents also affects cell viability, often presenting severe
limitations for large scale production purposes. 
Besides chemical synchronisation, several studies suggest hypothermia as a 
potentially useful tool to manipulate mammalian cell cycle distribution 
(Rao and Engelberg, 1965; Sisken et al., 1965; Watanabe and Okada, 1967).
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Typically, mammalian cells are grown at 37ºC, mimicking mammalian body 
temperature. At “sub-optimal” temperatures (25-33ºC) there is a 
prolongation of the cell cycle duration as a result of the temporal dilation 
of the G1, S and M (mitosis) phases, with G2 being the least and M the most 
sensitive phases to temperature shift (Rieder and Cole, 2002), undergoing 
the major increase in duration (Rao and Engelberg, 1965; Sisken et al., 
1965). However, theses occurrences are very dependent on the cell line 
considered. For example, incubation of human diploid fibroblasts (Enninga 
et al., 1984) or of a mouse leukemic cell line (Watanabe and Okada, 1967)
at 31ºC induced cell cycle arrest in G1/G0 phase; on the other hand,  when 
HeLa cells were incubated at sub-normal temperatures there was an 
accumulation of cells in the M phase (mitosis) (Rao and Engelberg, 1965).
In this work, we report on the effect of the cell cycle on AdV production. 
First, in order to establish the best cell cycle phase for AdV infection, 293 
cells were chemically synchronised. Then, due to the inherent problems 
associated with the use of these chemicals compounds for production 
purposes, a synchronisation strategy based on temperature shift was 
developed and evaluated in terms of AdV production at high cell densities 
in 2 L bioreactors.
2. MATERIALS AND METHODS
2.1. Cell line and medium
Anchorage-dependent 293 cells, purchased from Stratagene (Catalog 
#240085), were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% (v/v) heat-inactivated (56 ºC, 30 min.) Foetal 
Bovine Serum (FBS) (all from Invitrogen, Glasgow, UK) and 4.5 g/L of 
glucose (Merck, Darmstadt, Germany) at a humidified atmosphere of 5% 
CO2 in air at 37ºC. 293 cells were routinely propagated twice a week after 
trypsin/EDTA (Invitrogen, Glasgow, UK) addition at room temperature. 
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Suspension adapted 293 cells were grown in CD 293 (Invitrogen, Glasgow, 
UK), supplemented with 4 mM of glutamate (non-ammoniagenic medium) 
(Sigma-Aldrich, St. Louis, MO) at a humidified atmosphere of 8% CO2 in air 
at 37ºC in shake flasks (Corning, NY). Cells were routinely propagated twice 
a week using an inoculum of 0.5×106 cell/ml.
2.2. Adenoviral Vector
Recombinant AdV expressing the GFP protein were generated by 
homologous recombination of plasmid and digested DNA in E. coli strain 
BJ5183 (rec+). The GFP shuttle vector was first cloned into a transfer 
vector; the resulting plasmid was then linearized with a restriction enzyme 
(Swa I) and co-transformed into E. coli together with the plasmid 
containing AdV (pKP1.3). Recombinants were selected with ampicillin and 
screened by restriction enzyme analysis. The recombinant AdV construct 
was subsequently cleaved with Pac I to expose its ITR (Inverted Terminal 
Repeats) and transfected into 293 cells to produce viral particles.
2.3. Chemical synchronisation of 293 cells
For chemical synchronisation, 293 cells were seeded in 6 well plates at 
1106 cell/well, with a culture volume of 2 mL of DMEM supplemented with 
10% (v/v) FBS and 1% (v/v) antibiotic solution (10000 µg/mL streptomycin 
and 10000 U/mL penicillin) (Sigma-Aldrich, St. Louis, MO). One day after, 
seeded cells were incubated with each inhibitor at three different 
concentrations during 6, 12, 24 and 48h. A control for each inhibitor where 
only the respective solvent was added to the cell culture was performed. 
The experimental design is summarised in Table 4.2.1. After the incubation 
period, 293 cells were digested at room temperature with trypsin/EDTA 
and analysed by flow cytometry. 
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Table 4.2.1. Reversible chemical inhibitors used and correspondent cell cycle 
arrest point. Stock solutions, tested concentrations and control experiments are 
shown for each case.
Inhibitor 
Type
Target 
Arrest Point
Inhibitor Stock 
solution
Tested 
concentrations
Control
Mimosine Late G1
100 mM in a PBS 
solution 0.1% 
(v/v) in DMSO
1 mM
1 M
1 nM
PBS 0.1% 
(v/v) in 
DMSO
Hydroxyurea
G1/S 
transition
100 mM in a PBS 
solution 0.1% 
(v/v) in DMSO
1 mM
1 M
1 nM
PBS 0.1% 
(v/v)  in 
DMSO
Aphidicolin
G1/S 
transition
2.96 mM in DMSO
0.1 mM
1 M
1 nM
DMSO
Staurosporine G2
0.214 mM in 
ethanol 96% (v/v)
10 mM
1 M
0.1 M
Ethanol 
96% (v/v)
Nocodazole
G2/M 
transition
13.3 mM in a PBS 
solution 0.1% 
(v/v) in DMSO
1 mM
1 M
1 nM
PBS 0.1% 
(v/v)  in 
DMSO
2.4. Infection of chemically synchronised 293 cells
Infection of chemically synchronised cells was performed by seeding 293 
cells in 6 well plates at 1106 cell/well, with a culture volume of 2 mL of 
DMEM supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic solution
(10000 µg/mL streptomycin and 10000 U/mL penicillin). One day after, the 
best inhibitory conditions, determined beforehand, were added: 1 mM 
hydroxyurea during 48h, 0.1 mM aphidicolin during 12h and 1 µM 
staurosporine during 48h. In the experimental controls only the solvents 
were added. After the incubation period, cells were centrifuged at 200 g 
during 10 min. at 4ºC and suspended in 500 µL of fresh DMEM without FBS 
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and reseeded in a new well. Then, cells were infected with AdV using a 
multiplicity of infection (MOI) of 10. 30 min. afterwards, 1 mL of DMEM 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic solution (10000 
µg/mL streptomycin and 10000 U/mL penicillin) was added to each well. 
Infected 293 cells were then harvested at several times after digestion at 
room temperature with trypsin/EDTA. 
2.5. Temperature Synchronisation of 293 cells
For temperature synchronisation, 293 cells adapted to grow in suspension 
were inoculated at 0.5×106 cell/ml in 125 mL shake flasks with a working 
volume of 40 mL in a humidified atmosphere of 8% CO2 in air at 37ºC. Once 
the concentration of 2×106 cell/ml cells was reached, incubation at 29, 31, 
33, 35 e 37ºC was carried out for 72h, and the cell cycle followed by flow
cytometry.
2.6. Infection of 293 cells synchronised by temperature shift
Infection of 293 cells synchronised by temperature shift was done in 2 L 
bioreactors (Braun, Melsungen, Germany). For this purpose, two 
bioreactors were inoculated at 0.5×106 cell/ml with 293 cells adapted to 
grow in suspension. Once the population reached the concentration of 
3×106 cell/ml, one of the bioreactors (control) was infected and the other 
was synchronised at the S phase of the cell cycle and infected. All the 
infections were done using a MOI of 10 and AdV harvested at 48 hpi. 
Synchronisation was performed by firstly lowering the culture temperature 
to 31ºC during 67h and then restoring it to 37ºC during 72h.  The agitation 
rate was maintained at 110 rpm (NRe = 6800); pH was controlled at 7.2 by 
aeration with a CO2 gas-mixture and NaOH 0.2 M; the dissolved oxygen was 
controlled at 80% air saturation.
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2.7. Flow cytometric analysis
To quantify the cell-cycle distribution, cells were stained with propidium 
iodide to measure the DNA content by flow-cytometric analysis (FACS). 
Cells were centrifuged at 200 g for 10 min. at 4ºC, washed with ice-cold 
PBS and stained with ice-cold Vindelov’s solution (Vindelov et al., 1983): 1 
g/l trisodic citrate, pH 7.6; 50 mg/l propidium iodide (all from Sigma-
Aldrich, St. Louis, MO); 0.1% NP 40 (Roche Diagnostics, Germany); 700 U/l 
RNase A (Sigma-Aldrich, St. Louis, MO); 0.01 M NaCl (Merck, Darmstadt, 
Germany) for a final cell concentration of 1106 cell/ml. All FACS analyses 
were performed on a CyFlow® Space (Partec, Germany) equipped with a 
blue solid state laser set at 488 nm. Data analysis was performed using 
FlowMax® software (Partec, Germany).
2.8. Virus culture samples preparation
Infected 293 cells were harvested at 48 hpi and centrifuged at 1000 g for 
10 min. at 4ºC. The resulting cell supernatant was distributed into small
aliquots and stored at -85ºC for titration of extracellular virus. The 
resulting cell pellet was resuspended in a known volume of 10 mM Tris 
buffer, pH 8.0 supplemented with 2 mM MgCl2 (Merck, Darmstadt, 
Germany) and 0.1% (v/v) Triton (Sigma-Aldrich, St. Louis, MO). Cells were 
disrupted by vortexing for 1 min. and cell debris removed by centrifugation 
at 3000 g for 10 min. at 4ºC. The resulting cell lysate supernatant was 
dispensed into small aliquots and stored at -85ºC for quantification of 
intracellular viral content.
2.9. Adenoviral vector titration
AdV titration was done using anchorage-dependent 293 cells seeded in 24 
well plates at 0.25×106 cell/ml. One day later, seeded cells were counted 
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by haemocytometer and infected with 1 ml of serial dilutions of the AdV in 
infection medium (DMEM + 10% FBS). After 17 to 20 h of incubation 293 
cells were then harvested after digestion at room temperature with 
trypsin/EDTA and immediately analysed in the flow cytometer. Flow 
cytometric data was acquired using a CyFlow® Space. The green 
fluorescence signal was collected by a photomultiplier tube after passing 
through a 525 ( 20) nm band pass filter (FL1). GFP fluorescence of 3104
single viable cells per sample selected on FS versus SS scatter basis were 
analysed and high fluorescent cells were gated. The cytometric parameters 
were set to provide accurate discrimination between non-fluorescent 
negative cells and positive GFP-fluorescence cells on a FL1 versus FSC 
density plot in order to estimate the proportion of infected cells. Data 
analysis was performed using FlowMax® software.
2.10. Cell concentration and viability determination
Cell concentration and viability were determined by counting cells on a 
Fuchs-Rosenthal haemocytometer (Brand, Wertheim, Germany) using the 
trypan blue (Invitrogen, Glasgow, UK) dye exclusion method.
3. RESULTS AND DISCUSSION
3.1. 293 cell synchronisation with chemical compounds
To synchronise 293 cells at each phase of the cell cycle, 293 cells were 
incubated with different cell cycle inhibitors (mimosine, hydroxyurea, 
aphidicolin, staurosporine and nocodazol) at different concentrations 
(Table 4.2.1). As shown in Figure 4.2.1, the higher synchronisation was 
obtained: i) in the G1 phase (81% of the population) by incubation of 1 mM 
hydroxyurea during 48h; ii) in the S phase (47% of the population) by 
incubation of 0.1 mM aphidicolin during 12h; and iii) in the G2 phase (66% 
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of the population) by incubation of 1 µM staurosporine during 48h. For the 
other inhibitors tested, mimosine and nocodazol, no synchronisation was 
obtained at the concentrations and incubation periods tested, meaning 
that perhaps the concentrations tested were lower than the ones necessary 
to arrest cells; since synchronisation in each phase of the cell cycle had 
been achieved with the other 3 inhibitors, no further assays were 
performed with mimosine and nocodazol. 
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Figure 4.2.1. Proportion of 293 cells in the G1 ( ), S ( ) and G2 ( ) phases of the 
cell cycle, after incubation with the specified cell cycle inhibitor during 6, 12, 24 
and 48h.
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Despite the fact that aphidicolin was reported to inhibit the cell cycle in 
the G1/S phase transition (Jackson, 1995), our results show that this 
inhibition occurs during the S phase, possibly because even the highest 
aphidicolin concentration tested (0.1 mM) is still below the concentration 
needed for the complete inhibition of all the active DNA polimerase-; thus
the cell cycle can pass through the G1/S phase transition and enter a 
longer lasting S phase since less DNA polymerase- is active, resulting in an 
accumulation of cells in the S phase. 
3.2. Adenovirus vector production in chemically synchronised 293 
cells
Table 4.2.2: Cell concentration at the time of addition of inhibitors (Initial cell 
concentration) and after cell synchronisation (Final cell concentration). Control 
for each inhibitor was performed with addition of the respective solvent.
Initial cell concentration 
(×106 cell/ml)
Final cell concentration 
(×106 cell/ml)
Hydroxyurea 1.2 1.01
Aphidicolin 1.0 0.632
Staurosporine 1.3 0.621
Hydroxyurea Control 1.0 2.31
Aphidicolin Control 1.0 1.52
Staurosporine Control 1.0 2.41
1Cell concentration determined 48h after inhibitor/solvent addition.
2Cell concentration determined 12h after inhibitor/solvent addition.
To define the optimal cell cycle phase for AdV infection, AdV productivity 
using those chemically synchronised 293 cells was evaluated by infecting in 
each phase of the cell cycle with a MOI of 10, after medium exchange that 
was carried out to remove the inhibitor. Despite the fact that 
synchronisation decreases cell viability (Table 4.2.2), the results obtained 
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(Figure 4.2.2) show that the highest cell specific productivity was obtained 
when aphidicolin (S phase synchronisation) was used, a 2.6 fold increase on 
cell specific productivity being obtained when compared to the non-
synchronised control population. On the other hand, the use of 
staurosporine (G2 phase synchronisation) resulted in an 11 fold decrease on 
cell specific productivity while the use of hydroxyurea (G1 phase 
synchronisation) gave rise to a 17 fold decrease, when compared to the 
non-synchronised control population. These results confirm our earlier 
reported hypothesis (Zhang et al., 2006), that the S phase of the cell cycle 
is the optimal phase for AdV infection for increased productivity; this also 
substantiates the observed cell cycle progression towards S phase induced 
by Ad infection described by Berk (2005). 
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Figure 4.2.2. Profiles of cell specific productivity of chemically synchronised 293 
cells in G1 phase (hydroxyurea) (circles), S phase (aphidicolin) (triangles) and G2 
phase (staurosporine) (diamonds), and without synchronisation (control) (squares). 
Inhibitors were removed immediately before infection at a MOI of 10.
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3.3. Model for adenovirus production in chemically synchronised cells
In order to develop a model that can predict AdV productivities with 
different amounts of cells at the S phase of the cell cycle, cell specific 
productivity was plotted against the amount of cells at G1, G2 and S phases 
of the cell cycle (Figure 4.2.3).  
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Figure 4.2.3. Profiles of cell specific productivity of chemically synchronised 293 
cells in G1 phase (squares), G2 phase (triangles) and S phase (diamonds) of the cell 
cycle.
As can be seen in Figure 4.2.3, it is clear that only the amount of cells at 
the S phase of the cell cycle directly influences AdV productivity. The 
effect of the other two phases, G1 and G2, are inconsistent in terms of AdV 
productivity allowing the conclusion that increased amounts of cells in 
either G1 or G2 phases does not influence AdV productivity. Conversely, an 
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exponential relationship between the cell specific productivity and the 
amount of cells at the S phase of the cell cycle exists, for which 
description the following equation was considered:
dV/dS = kV (1)
where V corresponds to the cell specific productivity, S to the amount of 
cells at the S phase of the cell cycle and k is a constant, virus produced per 
amount of synchronised cells. By interpreting equation (1) is possible to 
obtain:
ln (V) = ln (V0) + kS (2)
By fitting the experimentally obtained data it is possible to determine ln 
(V0) (3.0432) and k (0.1266). Thus, the experimental correlation can ce 
represented in Figure 4.2.4.
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Figure 4.2.4. Correlation between cell specific productivity and amount of cells at 
the S phase of the cell cycle based on equation (2).
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3.4. 293 cell synchronisation by temperature shift
Having established S phase as the optimal phase for AdV infection in terms 
of cell specific productivity and, since chemical synchronisation decreases 
cell viability and is costly for large scale production purposes, temperature 
synchronisation was also evaluated. To achieve cell cycle arrest in G1/G0 
phase, 293 cells were incubated at 29ºC, 31ºC, 33ºC and 35ºC and 
compared with a control at 37ºC. As shown in Table 4.2.3, the only 
incubation temperature where cell death occurred was 29ºC; for all other
temperatures tested specific growth rates ranged from 2.2 (at 35ºC) to 
12.6 (at 31ºC) times less than the ones verified in the control (37ºC), which 
in fact was expected since the optimal growth temperature for most 
mammalian cell lines is between 35 and 37ºC (Rieder and Cole, 2002). 
Table 4.2.3: Specific growth rates obtained during a 72h incubation period at 
sub-optimal temperatures.
Temperature (ºC) Specific growth rate: µ (h-1)
29 -0.0018
31 0.0011
33 0.0050
35 0.0062
37 0.0139
Concerning cell cycle synchronisation, the results (Figure 4.2.5) show that 
the highest percentage of cells at the G1/G0 phase occurred at 31ºC and 67 
h of incubation, with a maximal synchronisation of 77%, representing a 1.3 
fold increase compared with the control for the corresponding period of 
time. To check whether a higher incubation period at 31ºC could increase 
the proportion of cells arrested in G1/G0 phase, cells were incubated 
during 100h at 31ºC, however no further increase was observed (data not 
shown). 
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Figure 4.2.5. Effect of incubation temperature on the proportion of 293 cells in 
the G1 ( ), S ( ) and G2 ( ) phase of the cell cycle.
Possible explanations for this observation can be the induction of p21, an 
inhibitor of the G1/S transition synthesis, reported for glioblastoma human 
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cells after a 4ºC cold shock during 1h (Ohnishi et al., 1998). Furthermore, 
studies with human or mouse embryonic fibroblasts incubated at 28ºC have
shown increased level of p53 (a transcription factor that blocks cell cycle 
at G1/S transition in case of damaged DNA) and p21, resulting in cell cycle 
arrest at G1/S transition; this does not take place in embryonic cells of p53 
knockout mice submitted to the same conditions (Matijasevic et al., 1998). 
All these studies indicate that cell cycle arrest in mammalian cells in 
response to cold shock is induced by the activation of pathways that 
regulate cell cycle checkpoints, as the ones mediated by p53. Once 
activated, this pathway induces synthesis of p21 which blocks G1/S 
transition by inhibition of cyclin dependent kinases (CDKs). This blockage 
persists until the p21 activity decays below a threshold value, after which 
cell cycle resumes.
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Figure 4.2.6. Cell cycle progression of 293 cells during 120h at 37ºC after a 67h 
cold shock at 31ºC. G1 phase is represented by (♦), the S phase by () and the G2 
phase by (▲).
As the aim was to obtain cell synchronisation in S phase, the cell cycle 
progression of 293 cells incubated at 37ºC, after a 67h cold shock at 31ºC,
was followed. As shown in Figure 4.2.6, cell cycle synchronisation in G1 
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phase is maintained up to 53h after the cold shock. Thereafter, an increase 
in the proportion of cells in S phase of the cell cycle can be observed, a 
maximum of 57% being obtained at 72h.
3.5. Adenovirus vector production in synchronised 293 cells by 
temperature shift
The effect on AdV production of this temperature synchronisation in the S 
phase at high cell densities was tested in 2 L bioreactors, where 293 cells 
were infected after S phase synchronisation was reached by a temperature 
strategy of 67h at 31ºC followed by 72h at 37ºC. A control bioreactor, 
without temperature shift, was also done at 37ºC. In both cases, cells were 
grown up to 3×106 cell/mL and infected immediately (control) or after 
synchronisation. It was observed that at these high cell densities the 67h 
cold shock at 31ºC decreased the cell concentration from 3 to 1.6×106
cell/mL (data not shown). Nevertheless, a significant increase in the 
percentage of cells at the S phase of the cell cycle was obtained for this
smaller cell population.
Table 4.2.4: Effect of 293 cell cycle synchronisation in S phase, by temperature 
shift, on cell specific productivity at a cell concentration at infection of 3×106
cell/mL.
cell specific 
productivity (ip/cell)
AdV volumetric 
productivity (ip/mL)
Control 3.0×103 8.4×109
S phase synchronised cells 2.2×104 3.5×1010
Infections were performed at MOI of 10 and AdV harvested at 48 hpi.
As shown in Table 4.2.4, a 7.3 fold increase on cell specific productivity 
(2.2×104 ip/cell) was obtained when cell cycle was synchronised in S phase 
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before infection, comparing to that obtained in the control bioreactor 
(3.0×103 ip/cell); although cell viability decreased almost by half after 
synchronisation, this improvement on cell specific productivity results in an 
overall 4 fold increase upon AdV volumetric productivity. Curiously, this 
increase on AdV productivity was obtained for an increase of only 1.7 times 
on the percentage of cells at the S phase of the cell cycle. Seidman et al. 
(2001) reported that both the high-affinity coxsackie-adenovirus receptor 
(CAR) for Ad fiber protein and the low-affinity v integrin receptor for Ad 
penton base protein showed increased cell surface expression at G2/M 
phase (1.5 fold and 2 to 3 fold increase respectively) when comparing with 
the G1 phase of the cell cycle. Although no results were shown for cells 
synchronised at the S phase of the cell cycle, it is expected that these Ad 
receptors also reach increased values at this phase when compared with 
the G1 phase of the cell cycle. This can explain the results obtained since,
in addition to an increased efficiency of S phase synchronised cells to 
support AdV production, AdV infection efficiency increases in the S phase 
synchronised cells.
Finally, by using the model developed previously, for a percentage of cells 
at the S phase of the cell cycle of 57% it was expected a cell specific 
productivity of 2.8104 ip/cell, 21% more than the obtained. This different 
may be due to the fact that the amount of cells at the S phase of the cell 
cycle obtained with the temperature shift strategy is out of the range. In 
addition, this small difference can be due to the fact that the 
synchronisation method used was different.
4. CONCLUSIONS
The results presented above confirmed that it is possible to obtain 
substantial cell cycle synchronisation for 293 cells by chemical means at G1 
(81%), S (47%) and G2 (66%) phases (Figure 4.2.1); furthermore, these 
results prove that S phase is the optimal cell cycle phase for AdV infection
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(Figure 4.2.2). In addition a mathematical model that can predict AdV 
productivities with S phase cell synchronisation was developed with 
success.
For large scale production purposes, a 293 cell cycle synchronisation in the 
S phase (57%) was also accomplished by incubating at 37ºC during 72h after 
a 67h cold shock at 31ºC (Figure 4.2.5 and 4.2.6).  This strategy yield a 7.3 
fold increase on cell specific productivity (2.2×104 ip/cell) compared to 
that obtained in a non-synchronised population (3.0×103 ip/cell) which had 
23% less cells in the S phase than the synchronised population at infection 
time. A significant drop on cell viability was observed after the 
temperature shift treatment (around 50%); nevertheless, due to the large 
increase in cell specific productivity, this strategy allowed a 4 fold increase 
on AdV volumetric productivity.
These results confirm the physiological state of the cell as an important 
factor on AdV production at high cell densities and the S phase of the cell 
cycle as the best phase for AdV infection. In addition, the data presented 
here show that the temperature shift method can be used for S phase 
synchronisation without the use of chemical substances. Nevertheless, 
since the culture temperature affects such cellular events as growth, 
viability, protein synthesis and metabolism, further studies are needed to 
achieve an efficient process for AdV production. 
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1. DISCUSSION
For early gene therapy clinical trials a production below 1015 virus particles 
per batch is suitable due to the relatively small number of patients 
involved, while some vaccine applications may require the development of 
larger amounts of virus particles; both cases require maximization of the 
AdV volumetric productivity. Both viral productivities, cell specific and 
volumetric, depend on the genetic AdV design and the cell line used to 
propagate the virus, as well as the medium formulation, scale and culture 
system used; the manipulation of these factors in process optimisation is 
required.
Almost all major media manufactures have commercialised specific serum-
free formulations designed and optimised for the cultivation of AdV, such 
as the CD 293 medium from Invitrogen and EX-Cell medium from JRH, as 
mentioned in Chapter II. Such formulations allow cell growth to reach high 
cell densities of up to 8×106 cell/ml in batch mode. However, cell specific 
productivity for virus production is dramatically reduced for densities 
higher than 1×106 cell/ml. Indeed the medium that allows for a higher cell 
density does not necessarily allow for higher virus productivity, as observed 
in the case of EX-Cell and CD 293 media where the medium responsible for
the higher cell specific productivity has the lowest cell density at the end 
of the batch growth phase; this is due to the fact that, most often media 
are designed and optimised for cell growth. As shown in Chapter III Part 1, 
during the virus production phase the specific consumption rates of several 
medium components (such as glucose and amino acids) were shown to 
increase leading to the exhaustion of some nutrients, such as threonine, 
glutamine and glucose, when infection was performed at CCI of 3×106
cell/ml. Nevertheless the refeed of these nutrients did not allow for a 
significant improvement on AdV production at such cell density. On the 
other hand, the refeed of these nutrients, mainly glutamine at infection, 
led to an increase on ammonia production which effects upon AdV 
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production was unknown.
Most of the reported studies concerning the effect of ammonia upon cell 
growth and productivity are conducted after ammonia addition to the 
culture medium. However this experimental approach does not mimick the
real cell behaviour as cell internal concentrations are different depending 
on where the ammonia is being produced by or added to the cells; thus,
large amounts of ammonia were needed to observe any inhibitory effect. In 
this thesis, ammonia specific productivity was significantly decreased by
adapting 293 cells to grow in CD 293 medium where glutamine was 
exchanged by glutamate. With this strategy, a prolonged lag phase, 
reduced growth rates and lower maximum cell densities were obtained. In 
addition, an increase in all amino acids specific consumption rate was also 
observed, particularly glutamate, which is produced in cells growing in 
glutamine supplemented media. On the other hand, no significant 
variations were observed in glucose specific consumption and lactate 
production rates in non-infected cells. By infecting these cells, at a CCI of 
3×106 cell/ml, an almost 2 times increase on AdV volumetric productivity 
was obtained, proving the importance of high  ammonia concentration, as 
the ones observed at this CCI, on AdV production at high cell densities.
By comparing both ammoniagenic (glutamine supplemented) and non-
ammoniagenic (glutamate supplemented) media in Chapter III Part 2, the 
mechanisms of ammonia inhibition of AdV production are discussed. 
Intracellular pH (pHi), observed to decrease with the increase on ammonia 
concentration during cell growth, was responsible for a series of 
phenomena that led to AdV losses at high cell densities when the 
ammoniagenic medium was used. These changes in the pHi were observed 
to be enough to activate both an acidic pathway of apoptosis and an 
enzyme capable to cleave the AdV DNA (DNase II); thus, cell death started
earlier and the amount of AdV DNA available for encapsulation decreased
significantly explaining the reduced cell specific productivity obtained.
Although a significant improvement on cell specific productivity was 
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obtained by adapting the cells to non-ammoniagenic medium, this 
improvement is still far from optimal, since the “ideal” situation would 
have been a three fold increase at CCI of 3×106 cell/ml. Therefore, in 
Chapter IV, the physiological state of the cells at the time of infection was 
evaluated by examining the cell cycle distribution at different cell 
densities. The maximum amount of cells at the S phase of the cells cycle 
was found around 1×106 cell/ml (the optimal concentration for AdV 
infection) and decreased with increasing cell density. By chemically 
synchronising the cells at each phase of the cell cycle we observed that the 
cell specific productivity was significantly increased when cells were 
infected after synchronisation at the S phase of the cell cycle. On the other 
hand, when cells were infected after synchronisation in either G2 or G1 a 
significant decrease in cell specific productivity was obtained, more 
pronounced for G1. These results clearly confirm S phase of the cell cycle 
as the optimal phase for AdV infection and support our previous hypothesis 
that the cell physiology at the time of infection is one critical parameter 
on the “cell density effect”. From these results the development of a 
simple method for cell synchronisation avoiding the use of chemical 
inhibitors would be instrumental. This was accomplished by using a 
temperature shift strategy, consisting in decreasing the temperature to 
31ºC during 67 h and increasing it again to 37ºC during 72 h. As a result, 
57% of the cells were synchronised at the S phase of the cell cycle, an 
increase of 23% when compared with non-synchronised cells. Although a 
drop on cell viability was observed, a 7.3 fold increase on cell specific 
productivity was obtained, corresponding to a 4 fold increase on AdV 
volumetric productivity when compared with infection of cells in the non-
ammoniagenic medium at a CCI of 3×106 cell/ml.
2. CONCLUSION AND FUTURE WORK
This thesis aimed to overcome the limiting factors on AdV production at 
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high cell densities, an issue which had been ongoing in the literature for a 
while. Two factors were found to play an important role on AdV production 
at high cell densities: ammonia and cell cycle. High concentrations of 
ammonia, as those observed at CCI of 3×106 cell/ml, were shown to induce 
cytoplasmatic acidification leading to cell death and AdV DNA degradation, 
leading to a decrease on the bioactive AdV production. On the other hand, 
the percentage of cells in the S phase of the cell cycle was observed to 
decrease with increasing cell density with a maximum at approximately 
1×106 cell/ml. The S phase was instrumental to improve AdV production at 
the time of infection and a substantial increase on cell specific productivity
was obtained when infection took place after a substantial cell population
synchronised in this phase. In addition, since the percentage of 
synchronised cells at the S phase of the cell cycle is higher at CCI of 3×106
cell/ml than the ones observed at CCI of 1×106 cell/ml, the cell specific 
productivity increased 4.8 times, a 7.6 fold increase being obtained in 
terms of AdV volumetric productivity.
Future work will focus on the optimisation of S phase synchronisation. The 
maintenance of cell viability during infection at high cell densities in S 
phase of the cell cycle synchronised cells will led to considerably increased 
AdV titers. Temperature changes would affect such cellular events as 
growth, viability, protein synthesis and metabolism. Thus, in order to 
achieve an efficient process for AdV production, cell synchronisation needs 
to be further improved.
3. SCIENTIFIC CHALLENGES ON AdV AS VACCINES
The major potential drawbacks for the use of AdV as a veterinary vaccine is 
the rare but possible emergence of E1 containing vectors, due to eventual 
minute homologous recombination events between the viral E1-containing 
(permissive) mammalian host cell genome and the virus itself, restoring the 
E1 gene to the viral genome and originating recombinant competent 
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adenovirus (RCA). Its appearance in batches is a chance process and is 
therefore unpredictable and difficult to control. This is a significant issue
for GMP manufacturing. It is also unwanted from a safety point of view, as 
upon coinfection of a cell, RCA causes the E1-deleted AdV to replicate in 
an uncontrollable way. In addition, RCA has been shown to cause 
inflammatory responses. Therefore, RCA generation during production of 
E1-deleted AdV has to be circumvented. To reduce or eliminate the 
problem of RCA, an E1-trasformed human cell line, PER.C6, was 
constructed (Fallaux et al., 1998) by transformation of primary human 
embryonic retinoblasts with limited homology with the viral sequences, 
thus reducing or eventually eliminating the emergence of RCA during virus 
amplification. Nevertheless, the licenses requested for using the PER.C6 
technology makes its use improbable for veterinary vaccine production.
The immune response to AdV or its transgenes is a limiting factor in the 
successful application of these vectors. Antivector immune responses can 
be broadly divided into cellular and humoral. While the cellular immune 
response limits duration of transgene expression, the humoral response 
may reduce the therapeutic efficacy of repeated vector administration. It 
is also emerging that the humoral immune response to viral vectors is not 
limited to responses against the viral vector components but also includes 
anti-transgene responses that can affect the persistence of transgene 
expression. One approach to enhance Ad-mediated gene transfer is to 
modulate the host immune response by immunosuppresion of the recipient 
organism such as cytokine treatment, T-cell depletion strategies and 
immunosuppressive drugs. Vectors with capsid components modified at 
specific capsid sites known to be targets for the anti-Ad-neutralizing 
antibodies might be useful in overcoming pre-existing, serotype-specific 
anti-Ad immunity. In addition, administration of different-serotype AdV, 
such as Ad 35, or different-species AdV, such as canine AdV, may 
circumvent the local host immunity elicited by a first vector 
administration. There are more than 100 different Ads isolated from man, 
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sheep, cattle, dog, horse, bird, etc.
Recent efforts to better characterize the in vivo host responses and 
barriers to Ad infection have defined a number of hurdles to the use of AdV 
for both gene therapy and vaccination. With this groundwork laid, 
systematic exploration of these barriers will hopefully lead to development 
in the means to circumvent them. This is already a very active area of 
research and is likely to continue to be productive.
Up to now, many viruses have been used as viral vectors for delivery of 
foreign antigens (see Yokoyama et al. (1997) for a review). The 
development of these recombinant vaccines may be of value in the 
veterinary field, especially when attenuation of the target pathogen is not 
possible, when immunity to one or more pathogens must be raised at the 
same time or when satisfactory quantities of the target pathogen or the 
live vaccine cannot be produced easily or safely. For their practical use, 
potential safety issues must be overcome, such as reversion of virulence or 
recombination with field-type viruses spread in the environment and 
genetic stability. The selection of a good viral vector as a recombinant 
viral vaccine should be determined by the host range of the vector, safety 
consideration, replication properties, stability, the amount of foreign DNA 
which can be inserted and the place where the primary immune reaction is 
induced by antigens expressed by the vector. 
Exciting advances in biotechnology are enabling the development of new 
vaccines with enormous possibilities that were once considered 
unthinkable. These newer vaccine approaches have benefited from an 
improved basic understanding of the immunology of antigen presentation 
and the factors important in sustaining memory immune responses. The 
continued improvement in our understanding of the nature of protective 
immunity against various infectious diseases, such as HIV and malaria,
should allow the rational design of vaccines and immunization strategies 
that generate protective immune responses against infectious diseases for 
which no vaccines yet exist.
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1. INTRODUCTION
Recombinant adenoviral vectors (AdV) are highly efficient for gene transfer 
in a broad spectrum of cell types and had become one of the vectors of 
choice for delivery and expression of foreign proteins for gene therapy and 
vaccination purposes. The market requirements for AdV are constantly 
increasing causing a high demand of methodologies for the production in 
large scale of concentrated vectors. 
The importance of infection kinetics on viral and protein production and 
the significance of variables such as MOI (Multiplicity Of Infection) and HPI
(Hours Post Infection) in process optimisation have been demonstrated in 
previous studies with other viral/eukaryotic expression systems e.g. 
baculovirus-insect cells (Cruz et al., 1999), reinforcing that an optimized 
strategy of MOI and HPI is mandatory to increase production yields. Other 
important parameter affecting the viral infection process is serum 
concentration in the culture media (Petricevich et al., 2001; Maranga et 
al., 2002).
In this work, AdV production kinetics was investigated. Factors such as 
medium composition, serum content, MOI, and harvest time were studied. 
A first generation recombinant adenovirus type 5 was used.
2. MATERIALS AND METHODS
Cell Growth: 293 cells (ATCC-CRL-1573), were grown in MEM supplemented 
with 2 mM glutamine and 5% (v/v) FBS (all from Gibco, UK), at a humidified 
atmosphere of 5% CO2 in air at 37ºC or in CD 293 (a serum and protein-free 
medium Invitrogen, UK) supplemented with 2 mM glutamine at a humidified 
atmosphere of 8% CO2 in air at 37ºC; AdV Quantification: AdV titration was 
performed by the end-point dilution method (TCID50) using 96 well plates 
and 293 cells. The titer was calculated according to the method of Reed 
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and Muench (Summers and Smith 1987). Virus titer were normalized to the 
maximum one in the experiment. 
3. RESULTS AND DISCUSSION
3.2.1. Effect of MOI on AdV Production
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Figure A.1. Effect of MOI on normalized virus titer (◊ intracellular, 
extracellular). 
To evaluate the effect of MOI on AdV production, 293 cells were infected 
with a MOI of 1, 5, 10 and 20. The AdV production profiles are shown in 
Figure A.1. The maximum vector titer increased by a factor of 102 when 
the MOI was increased from 1 to 5. Further increase in MOI did not affect 
vector titer but caused a shift of the optimal harvest time; taking into 
account the AdV net output (AdVOut/AdVIn) it is clear that the best yields 
are obtained when a MOI of 5 is used. The profiles of AdV release into the 
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supernatant (due to cell lysis) were similar for MOI of 1, 5 and 10. The 
results show that for 36 hpi the amount of AdV released into the 
supernatant is not significant as compared with the intracellular content.
3.2.2. Effect of Serum on Cell Growth and AdV Production
In order to understand the effect of serum concentration on AdV 
production, cells were grown in MEM supplemented with 10% FBS and at the 
time of infection (MOI 5) the total volume of the culture medium was 
replaced by MEM supplemented with 10, 5, 1 and 0% of FBS. AdV were 
harvested at 48 hpi. The highest AdV yields were obtained in MEM 
supplemented with 5% FBS (Figure A.2). 
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Figure A.2. Normalized virus productivity () and cell viability () at different 
serum concentration for a MOI of 5 at 48 hpi.
AdV production decreased by a factor of 103 when 0 and 1% FBS 
concentrations were used indicating the importance of serum on viral 
infection as extensively reported in the literature (Petricevich et al., 2001; 
Maranga et al., 2002). Interestingly a decrease on AdV production was 
observed for 10% FBS containing medium suggesting that, when in excess, 
some serum components (e.g. proteins) can compete with AdV for cell 
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receptors by blocking viral receptors and consequently decreasing the 
probability of viral entrance into the cell. Also, a concomitant decrease in 
cell viability was observed with the decrease in serum content (Figure A.2). 
However, supplementing cell culture media with serum presents several 
drawbacks as mentioned before. Recently, several serum and protein free 
culture media became commercially available, as an alternative approach 
to serum containing medium formulations. Thus, in order to avoid the use 
of serum, CD 293, a serum and protein free medium, was compared with 
MEM supplemented with 5% FBS in their ability to grow 293 cells in T-Flask, 
since 293 cells were not able to grow in suspension with MEM medium (data 
not shown). As shown in Figure A.3, CD 293 presented the highest specific 
growth rate and allowed the highest maximum cell number, being a good 
alternative to the serum supplemented media in terms of cell growth.
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Figure A.3. Growth curves of normalized 293 cells obtained in two different 
culture media: (♦) MEM + 5% FBS and () CD 293.
To evaluate the performance of both media to produce AdV in T-Flasks, 
cells were grown in MEM supplemented with 5% FBS or CD 293 and infected 
at confluency around 90% with a MOI of 5 after media exchange. The 
results are presented in Figure A.4. The highest AdV yields were obtained 
in CD 293 medium confirming the potentiality of this media to “support” 
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AdV production. The fact that CD 293 is a protein free medium could 
explain the higher AdV productivity obtained, since components that may
compete with AdV for cell receptors are not present.
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Figure A.4. Normalized virus titer at a MOI of 5 with () CD 293 and (♦) MEM+5% 
FBS.
4. CONCLUSIONS
The best AdV production yields were obtained for a MOI of 5 at 48 HPI. 
Serum concentration affected AdV production yields and also cell viability. 
The best FBS concentration was 5%. Surprisingly, AdV infection seems to be 
hindered by the presence of a higher serum concentration (10%). CD 293, a 
serum and protein free medium, prove its potentiality as the best 
alternative for AdV production, not only because it supports higher AdV 
yields but also because it is possible to simplify the downstream process, 
since virus and prions contamination are avoid in the bioprocess.  
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Abstract
Methodologies for production of concentrated adenovirus vectors (AdV) 
with warranted purity and efficacy at low cost are needed as the market 
for AdV is expanding fast. However, production of AdV that maintain a high 
specific yield is limited to cell densities in the range of 1×106 cell/ml; the 
nature of the factors for this remains unknown. The aim of this work is to 
study the effect of addition of vitamins or lipids at the time of infection at 
high cell densities in order to see if these nutrients are limiting. No 
improvement on AdV productivity was observed. Furthermore, a significant 
decrease on cell specific productivity after vitamin addition was observed.
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1. INTRODUCTION
AdV became one of the vectors of choice for delivery and expression of 
foreign proteins for gene therapy and vaccination purposes (Ferreira et al., 
2005a). Nevertheless, the production of AdV is currently limited by the so-
called “cell density effect” (Nadeau and Kamen 2003). Several approaches 
have been made in order to overcome this drop in cell specific productivity 
concomitant with increased cell concentration at infection (CCI): Garnier 
et al. (1994), demonstrated that medium replacement at infection and the 
addition of glucose at 24 hours post infection (hpi) together with periodical 
pH adjustments, allowed a sustained maximum specific productivity at 
1.6106 cell/ml; whereas Nadeau et al. (1996), further improved this 
strategy by also adding essential amino acids at 24 hpi thereby stabilising 
volumetric productivity at cell densities above 2106 and below 3106
cell/ml. Such results hint at the existence of substrate limitation and/or 
byproduct inhibition at high cell densities. In our latest study, by adapting 
the cells to non-ammoniagenic medium, a 1.8 fold increase on AdV 
volumetric productivity at CCI 3×106 cells/ml was obtained (Ferreira et al., 
2005b), although the “ideal” situation would have been an increase of 3 
times at this CCI; thus, ammonia is an important parameter to be 
considered for infection at high cell densities, but not the only one.
Future improvements to the culture process may come from analysis of
other nutrients than the usual glucose, lactate, ammonia and amino acids. 
A cocktail of different nutrients are present in the culture media that may 
have an important impact on AdV production as vitamins, lipids, hormones 
and growth factors. Thus, in this work, addition of vitamins and lipids at 
the time of infection at high cell densities was evaluated in order to see if 
these nutrients are limiting the AdV production at high cell densities.
Annex B
177
2. MATERIALS AND METHODS
Suspension adapted 293 cells (ATCC-CRL-1573) were grown and infected in 
non-ammoniagenic medium in a 2L bioreactor (Braun) as described in
Ferreira et al. (2005b). For the fed-batch operation mode, Vitamins and 
Lipids cocktail solutions (all from Gibco) were used; AdV titration was 
performed by the end-point dilution method (TCID50) using 96 well plates 
and 293 cells. The titer was calculated according to the method of 
Spearman and Kraber, as described in Darling et al. (1998).
3. RESULTS AND DISCUSSION
Vitamins and lipids are important nutrients for cell growth. Moreover, lack
of such nutrients may affect cell productivities. Thus, two different fed-
batch operation modes were tested with addition of: (1) vitamins or (2) 
lipids cocktail at the time of infection at CCI 3106 cell/ml.
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Figure B.1. Cell specific productivity after addition of vitamins (●) or lipids () at 
the time of infection, at CCI 3×106 cell/ml. The control () was performed without 
any nutrient addition.
As can be observed in Figure B.1, neither the addition of vitamins nor of 
lipids, at the time of infection, improved the cell specific productivity at 
this CCI. On the other hand, a significant cell specific productivity decrease 
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was observed after the addition of vitamins. Following the cell metabolism 
after infection it was possible to observe that none of the measured 
parameters was shown to be responsible for this significant decrease (Table 
B.1), suggesting that vitamins may have an effect on AdV stability.
Table B.1. Measured parameters during infection at CCI 3×106 cell/ml 
concomitant with addition of vitamins.
Parameters Result
Glucose Not limiting
Lactate Below inhibitory values
YLac/Glc Unchanged
Amino acids Not limiting
Ammonia Below inhibitory values
Osmolality Below inhibitory values
Cell growth No effect
In order to evaluate the effect of vitamins on AdV stability, AdV were 
incubated with the vitamins cocktail at different concentrations during 48h 
at 37ºC and pH 7.2 (Figure B.2). Although a small decrease on AdV titer was 
observed this was not statistically different from the ones in the control, 
meaning that vitamins have no influence upon AdV stability. 
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Figure B.2. AdV stability during incubation with medium supplemented whit 0× (●) 
(control), 1× (), 1.5× (∆) and 2× (♦) of vitamins.
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Several studies reported some vitamins as virus inactivators, e.g. 
riboflavin, present in our vitamins cocktail, was shown to selectively 
induce damage only to nucleic acids (Dardare and Platz 2002) and probably 
this may explain the significant decrease on cell specific productivity, since 
AdV DNA damage might be occurring during AdV replication.  
In conclusion, from the lipids present in the cocktail no one seems to be 
limiting on AdV production at high cell densities, since no improvement on 
cell specific productivity was observed after addition of these nutrients. 
Concerning addition of vitamins an inhibitory effect appears to be present 
on AdV production after the addition of these nutrients.
4. ACKNOWLEDGEMENT
The authors are grateful to Dr Tom Barret (Institute for Animal Health -
Pirbright, UK) for providing the recombinant adenovirus. The authors 
acknowledge the financial support received from the European Commission 
(Project ICF599A4PR01) and from Fundação para a Ciência e Tecnologia –
Portugal (Project POCTI/BIO/46515/2002 and student grant 
SFRH/BD/10614/2002).
Effect of vitamins or lipids addition on AdV production at high CCI
180
5. REFERENCES
Dardare, N. and Platz, M.S., 2002. Binding affinities of commonly employed 
sensitizers of viral inactivation. Photochem Photobiol 75, 561-4.
Darling, A.J., Boose, J.A. and Spaltro, J., 1998. Virus assay methods: accuracy and 
validation. Biologicals 26, 105-10.
Ferreira, T.B., Alves, P.M., Aunins, J.G. and Carrondo, M.J.T., 2005a. Use of 
adenoviral vectors as veterinary vaccines. Gene Ther 12 Suppl 1, S73-83.
Ferreira, T.B., Ferreira, A.L., Carrondo, M.J.T. and Alves, P.M., 2005b. Effect of 
refeed strategies and non-ammoniagenic medium on adenovirus production at high 
cell densities. J Biotechnol 119, 272-80.
Garnier, A., Cote, J., Nadeau, I., Kamen, A. and Massie, B., 1994. Scale-up of the 
adenovirus expression system for the production of recombinant protein in human 
293S cells. Cytotechnology 15, 145-155.
Nadeau, I., Garnier, A., Côté, J., Massie, B., Chavarie, C. and Kamen, A., 1996. 
Improvement of recombinant protein production with human adenovirus/293S 
expression system using fed-batch Strategies. Biotechnol Bioeng 51, 613-623.
Nadeau, I. and Kamen, A., 2003. Production of adenovirus vector for gene therapy. 
Biotechnol Adv 20, 475-489.
